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1.  Introduction and  aim 
The  conflicting  concepts  of  the  "medically  possible"  and  the  "economically  feasible"  
represent one of the crucial issues in modern medicine. Medicine today is able to offer cure for 
numerous diseases but even the wealthiest  national  economy in the world is unable to make the 
high technology used in health care available for all its citizens who are in need of it. In case of 
guaranteeing  quality  health  care,  it  is  essential  to  provide  access  for  everyone  to  efficient  
procedures that are based on facts and to put a stop to inefficient or harmful practice [1].  
"Evidence-based  Medicine"  (EBM)  as  the  English-speaking  world  has  labeled  this  
philosophy  prefers  the  application  of  the  best  evidences  that  are  based  on  facts  without  
encroaching upon the doctors'  independence  in decision-making.  The evidence-based  protocols  
can  contribute  to  the  establishment  of  health  welfare  and  their  application  can  optimize  the  
utilization  of  financial  and  intellectual  resources  and  diminish  useless  hospitalization  and  the  
practice of quantitatively unjustified and professionally objectionable drug prescription  [2,3,4].  
The main objective of quality health care is to guarantee the best possible health result at the 
lowest cost in such a way that those who are provided are satisfied with the nature and result of 
the rendered service. 
The last decade saw the growing appreciation of attempts to achieve high quality health care 
in Hungary as well. The available resources are tight and the health condition of the population is 
quite poor. The regional differences can be seen not only in the practice of health care but in the 
development of health condition parameters as well  [5,6,7].  
An important  systematic  device of improving quality is to control the processes,  and one of 
the possible ways by which  it  can be  achieved  is to  apply  evidence-based  practical  guidelines.  
Since the input in health care -  the patient who needs the care -  is a personal entity with features 
that influence the result of the care in several ways, the specification of processes that  are most 
likely to be able to produce optimal results is rather difficult,  and this task needs caution and the 
co-operation of several professions, and naturally it is time consuming. Nevertheless, even those 
practical guidelines that are produced according to the appropriate regulations, and applied in the 
appropriate manner can fail to achieve the expected results in certain cases [8,9]. 
By practical  guidelines we mean series of systematically developed statements that are based 
on scientific evidence and  expert  opinion and they can present  a suggestion with respect to  the 
certain steps of health care for both the providers and those who are provided in case of specific, 
well-defined circumstances, and with regard to special categories of patients [10]. 
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The guidelines make an attempt to standardize the processes by using scientific professional 
evidences, and their application render the achievement of optimal health and/or economic result 
probable. With the help of these guidelines the process  of health care becomes  controllable  and  
the determination of quality indicators and the standards that derive from these becomes possible 
[11,12]. 
The  objective  in using practical  guidelines  can  be  manifold.  Assisted  decision-making,  as  
mentioned in the definition, can be highlighted in the first place, in case of which those specific 
therapies  and  diagnostic  methods  are  given  preference  that  are  able  to  guarantee  the  biggest  
possible improvement in the health condition of the patient. A further goal can be the balancing 
of the differences that  can be  seen in clinical  practice,  the promotion  of  quality  guarantee,  and  
the  moderation  of health  care  costs  by  implementing  "the  best  for the  first  try"  principle.  The  
guidelines  can  serve  as  a  basis  for  institutional  certification,  as  evidences  in  connection  with  
medical malpractice cases, they can promote research activities and they are important means in 
medical training and in post-graduate medical training as well  [9,13].  
One  of the  criteria  of guideline development and guideline application  is  that  the  disease  
affects a large population of patients  and it is a public health problem. The application  of these 
guidelines  is  recommended  in  those  fields  of  public  health  where  there  are  considerable  
differences in  clinical  practice,  where  great  variability  is  shown  in the  outcome  of health  care  
among the various health institutions and where significant costs are involved. 
The development of practical guidelines and their application at a national level has not been 
integrated fully into the  system of professional control  in Hungary yet. In  1996 the Ministry  of  
Welfare  started  a  project  in  order  to  make  advance  on  the  activities  in  quality  matters  at  a  
national  level,  and  seven  hospitals  won the  support.  The  Ministry  initiated  the  adaptation  and  
implementation of guidelines developed by the US Agency for Health Care Policy and Research 
(AHCPR) in  1994 in those institutes that volunteered to test the practical  guidelines. The project 
was  named  "BORCSI"  after the  initials  of  the  involved  hospitals.  The  main  objective  of  this  
initiation  was  on  the  one  hand  to  examine  with  a  1-year  follow-up  surveyhow  the  foreign  
guidelines can be put into everyday practice, what effect they have on health care activities, how 
the practice  and results  of health  care  change,  how the  costs  develop  and on the  other  hand  to  
monitor the documentation discipline in reflection of all these [14].  
Following  expert  consultation  we  have joined  the  program  namely  the  examination  of  the  
evidence-based practical  guideline titled  "Heart Failure: Evaluation and Care of Patients with 
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Left-Ventricular Systolic Dysfunction". This survey includes the examination of the impact study 
of this guideline and investigates how the guideline can be implemented in Hungary. 
The aim of the study: 
1.  Evaluating  the  applicability  of  hospital  documentation  in  terms  of  how  the  impact  
study of the practical guideline can be accomplished. 
2.  Analyzing  the  practice  of  Hungarian  patient  care  before  the  implementation  of  
guideline  in  case  of  patients  with  chronic  heart  failure  on  the  basis  of  health  
documents found in the institutions. 
3.  Revealing  the  fields  where  changes  can  be  experienced  in  the  period  after  
disseminating  the  recommendations  of  the  guideline,  comparing  it  to  the  period  
before  in  relation  to  treatment,  care  and  therapy  carried  out  according  to  the  
specifications of the practical guideline, irrespective of the institution. 
4.  Analyzing the clinical practice of the hospitals participating in the study in the periods 
before and after disseminating the  guideline  and  consequently  revealing those  fields  
of  the  project  where  the  leveling  of  basic  differences between  the  hospitals  can  be  
attributed to the implementation and application of practical  guideline.  
The  present  study  demonstrates  the  features of  medicinal therapy  as  one  of  the  treatment  
options in case of patients with chronic heart failure. 
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2.  Literature  review  
2.1.  Epidemiology of heart failure 
Over  the  past  several  decades,  cardiovascular  diseases  have  become  the  leading  causes  of  
death in both sexes worldwide.  It can be clearly seen that the most frequent causes of death and 
disability are cardiovascular  diseases for middle-aged men. This disease has got a less dominant  
role among women before their menopause. In developed countries however, the number of age-
specific cardiovascular  deaths has decreased  as a result  of systematically  planned  and  well-
financed curative-preventive activity (e.g. in the USA by 50 % in the last 25 years). The clinical 
manifestation of  these  diseases  and  consequently  the  deaths  connected  to  them  appear  later  in  
life [15,16,17,18]. 
In the second half of the 20th century, the trends of premature death were strongly determined 
by premature death caused by the diseases of the circulatory system [19]. After the middle of the 
1960's  certain  differences  could  be  observed:  while  in  developed  European  countries  the  
favorable  changes  in  premature  death  were  mainly  due  to  the  fact  that  the  number  of  deaths  
caused by cardiovascular  diseases decreased,  in the Eastern European population it was  exactly  
this  disease  that  played  a  significant  role  in  the  increasing  number  of  deaths  
[20,21,22,23,24,25,26]. 
As  regards  premature  death  caused  by  diseases  of  the  circulatory  system  in  the  adult  
population,  from the  Central  European  countries  Hungary  is the  one that has  fallen behind  the  
developed European countries really drastically  [19,27].  
The  "Johan  Béla National  Program  Decade  of  Health"  wishes  to  give  high  priority  to  the  
suppression of cardiovascular  diseases and deaths within the framework of its preventable  death  
section [28].  
Today  heart failure  represents  a  significant  and  rapidly  increasing  public  health  problem  
worldwide  even  if  mortality  due  to  cardiovascular  diseases  has  considerably  decreased  in  
developed  countries.  On  the  basis  of  current  epidemiological  research  it  can  be  seen  that  the  
incidence  and prevalence  of heart  failure show an increasing tendency  both  in the USA  and in  
Europe as well  [15,29,30,31,32,33].  1.5-2 % of the American population  suffers from clinically 
diagnosed  heart  failure  but  the  number  of  patients  with  left-ventricular  (systolic  or  diastolic)  
dysfunction is  even higher.  Their  condition  can be  verified by  modem  diagnostic  methods  but  
they  either  do  not  manifest  the  signs  and  symptoms  of  heart  failure,  or  do  not  recognize  the  
already existing signs and symptoms  [29,30,31,34].  
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According to the results of the Framingham Heart Study the yearly incidence of heart failure 
in the average population is  1.6 %o  and  gradually increases  with age: between the age of  35-65  
there are 3/1000, while over 65 there are  10/1000 new cases every year. For the elderly, over 75 
the incidence is  10 %, and heart failure is the most common cause for their hospital admission as 
well. The incidence of the disease is higher in men  [31,33,35,36,37,38].  
Heart failure is also notable for its high mortality rate. Although serious attempts have been 
made in order to investigate the etiology  of this common disease, to diagnose  and provide  cure  
for it, the mortality is still high and the  5-year mortality rate exceeds  50 %. Its prognosis  is the 
same as that of cancer. Death occurs in 40-70 % because of progressive circulatory failure, and it 
occurs suddenly in 30-60 % of all cases mainly due to malignant arrhythmia  [33,35,36,39].  
By  the  end  of  the  third  year  after  the  onset  of  the  symptoms  only  one  fifth  of  the  
decompensated male patients are alive, and the number of those is high who have asymptomatic  
cardiac dysfunction and in their cases in the coming  1-5 years symptomatic heart failure can be 
expected to develop presumably  [39,40,41]. The five-year survival rate is 25 % in men and 38 % 
in women. The average survival period is  1.7 years for men and 3.2 years for women [42].  
According  to  the  estimate  of  the  National  Heart,  Lung  and  Blood  Institute  more  than  one  
million patients suffering from heart failure need clinical care annually, and more than 5 % of all 
hospital  admissions  are  due  to  heart  failure.  One-third  of  the  patients  need  re-admission  and  
clinical care within 90 days  [32,33,43].  
The results of those European epidemiological  studies that are few in number  (carried  out in 
North-Finland and Sweden) are similar to the outcome of the Framingham Study. According to a 
bulletin issued by the European  Society of Cardiology in  1995 the number of patients  receiving  
treatment for heart failure is minimum 2 million in the European countries but this number may 
as well exceed  10 million. The prevalence of heart failure in Europe is 0.6-17  %o for those under 
the age of 65 while it is 28-190 %o for those over 65 [33,44].  
In  Hungary  there  are no  data  available  at  population  level  on the basis  of  which  the  exact  
indicators  of  incidence  and  prevalence  can  be  determined  as  far as  diseases  of  the  circulatory  
system are concerned. But it can be presumed that the situation cannot be better in Hungary than 
in the more developed  countries  since we know that the number  of the main diseases that  may  
lead to heart failure such as ischemic heart disease and hypertension  is very high  [35,36]. After 
extrapolating  data  of  the  Western  world  and  taking  into  consideration  the  arteriosclerosis  
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mortality data it can be stated that the number of those suffering from heart failure in Hungary is 
at least 300 000 or even more [34].  
The serious problem presented by heart  failure had been neglected  for a long time in health 
care.  Today  when  a  lot  of  hospital  beds  are  occupied  by  patients  with  heart  failure  and  this  
tendency  seems  to  be  increasing,  more  consideration  has  to  be  given  this  problem  and  the  
treatment of this disease has become a major challenge in health care [45]. 
2.2.  The  concept  of  heart  failure,  its  characteristics  and  the  basic  theories  in  its  
therapy 
From a pathophysiological point  of view heart failure is a condition in which the  inadequate  
pumping function of the heart muscle  is responsible for not being  able to  transport  oxygenated  
blood into the peripheral organs as the body's metabolic needs acquire. 
From  a  clinical point  of  view  heart  failure  is  a  complex  clinical  syndrome  with  reduced  
quality  of  life  and  shorter  life  expectancy.  It  is  characterized  by  inadequate  left-ventricular  
function  and  deficient  neurohormonal  regulation,  exercise  intolerance,  fluid  retention  and  
shortened  life expectancy.  Typical  features include  complaints  and  symptoms  (dyspnoea,  basal  
wheezing,  edema)  related  to  the  pathological  expansion  of  intravascular  and  interstitial  fluid  
space and the consequences of insufficient tissue perfusion [32,35,46,47]. 
The criteria set up by the Framingham study concerning congestive heart failure have proved 
to be useful i.e. for the  establishment  of the diagnosis the co-existence  of two major criteria  or  
one major and 2 minor criteria are necessary. In everyday practice a less quantitative  evaluation  
is used, a functional classification, which classifies heart failure patients according to the severity 
of  their  cases  on the  basis  of  the  recommendation  made  by  the New  York  Heart  Association  
(NYHA) [48,49].  
In most cases heart failure is caused by the malformation and later the deficiency of the heart 
muscle,  which  is  called  left-ventricular dysfunction. There  are two types:  systolic  and  diastolic  
dysfunction, and their distinction is very important concerning the applied therapy. 
The  definition  of  chronic  systolic  heart  failure  comprises,  apart  from  clinical  symptoms,  
systolic  dysfunction as well,  where the  ejection  fraction  (EF) is  less than  35-40  %.  In order  to  
establish  the  diagnosis  it  is  essential  to  be  able  to  detect  the  objective  signs  of  cardiac  
dysfunction besides the existence of the physical  symptoms  of heart  failure either  in rest  or  on 
exertion  [32,35,46,50,51].  
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As  regards  the  etiology  of  heart  failure,  valvular  heart  defects  then  hypertension  were  
considered to be the most common causes for this disease earlier. Today however, ischemic heart 
disease  is  the  most  decisive  etiological  factor  [35].  Chronic  systolic  heart  failure  and  severe  
systolic left-ventricular dysfunction are of ischemic origin in 70 % of all cases, their prognosis is 
less favorable than that of non-ischemic origin, and modem medicinal therapy can improve these 
conditions only to a certain extent  [52].  
In recent  years  a number  of  official bodies  and professional  societies  have dealt  with  heart  
failure management such as the European Society of Cardiology (ESC) or the American College 
of  Cardiology/American  Heart  Association  (ACC/AHA)  thus  everyday  clinical  practice  is  
assisted by  guidelines  and practical  recommendations  elaborated  by these  American,  European  
and other cardiologist societies  [44,53,54,55].  
Therapy options in case of heart failure include non-medicinal treatment, medicinal  therapy,  
and invasive therapies, and heart transplantation  [33]. The main purpose of medicinal  treatment  
is to reduce mortality  (ACE inhibitors,  isosorbide-dinitrate/hydralazine),  to ease complaints  and 
to improve general physical condition (ACE inhibitors, diuretics, digoxin) [32]. 
Since the treatment strategy of heart failure has changed in recent years, the management has 
been altered as well  [36,40]. Earlier the main purpose of medicinal treatment was to improve the 
left-ventricular  systolic  dysfunction  (with  positive  inotropic  drugs)  and  to  stop  fluid  retention  
(with  diuretics)  because  by  doing  so the  key  symptoms  of the  disease  could  be  eased.  Today  
mainly angiotensin-converting  enzyme inhibitors (ACE inhibitors), aldosterone antagonists, beta 
blockers  are used  in  order  to  have  an effect on the  pathologically  increased  functioning of  the  
neuroendocrine  system besides taking earlier purposes into consideration  as well. The treatment 
aims at decreasing the  symptoms, preventing heart  failure, stopping progression,  improving the  
quality of life in a complex way and making life expectancy longer  [35,40,56].  
Since  cardiac  dysfunction  is  always  a  progressive  disorder,  following  early  diagnosis  a  
preventive intervention is necessary: treatment has to be started  at the earliest possible  stage by 
applying efficient dosage of drugs that have an effect on neurohormonal  action in an  aggressive  
way. Standard medication, which is a combination of drugs containing ACE inhibitors,  diuretics  
and  digitalis,  with  P  blockers  in  NYHA  II-III  stages,  is  able  to  prevent  the  progression  of  
asymptomatic left-ventricular dysfunction [34,40,49]. 
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2.3.  Description  of  the  most  important  pharmaceutical  combinations  used  in  the  
treatment of heart failure 
2.3.1.  Diuretics  
Diuretics have an undisputed benefit in the treatment of renal failure, renal diseases with salt-
water  retention  and  also  in  the  failure  of  the  heart's  pumping  function.  They  reduce  plasma  
volume and venous reflux, thus moderating pulmonary congestion and dyspnoea [41,57].  
Even  though  they  represent  the  most  efficient treatment  in  congestive  heart  failure,  their  
beneficial effect on the progression of the disease and on mortality has not been justified. 
Three main types of diuretics are used in the treatment of heart failure. 
Thiazides represent the first line therapy in mild congestive heart failure. They do not  cause  
significant diuresis and can be administered orally due to their good absorptional  characteristics.  
They are cheap and well combined with loop diuretics. 
In  moderate  or  severe  congestive  heart  failure  the  use  of  loop  diuretics  is  indicated.  
Administered  either  orally  or  intravenously  their  effect is  fast and  intensive  but  short,  and  the  
degree of the effect is always dependent  on the applied dose.  Loss of potassium  due to the fast 
effect may  lead to  arrhythmias.  In  case  of  long-term  administration  of  more than  80 mg  daily,  
loop diuretics are to be combined with potassium-retaining diuretics and ACE inhibitors. 
Potassium-retaining diuretics may not be used  alone in heart  failure, as their  effect is  slow 
and comparatively  mild. However,  given  simultaneously  with thiazides  and loop diuretics  they  
act synergistically as well as reduce the loss of potassium  [53].  
The American  guidelines AHCPR  and ACC/AHA focus on diuretics  and ACE inhibitors  in  
medicinal therapy. 
According  to  the  AHCPR  guideline,  complaints  caused  by  volume  overload  can  be  
significantly reduced by diuretics, the administration  of which  should be instituted  immediately  
on the  appearance  of  such  symptoms.  Patients  with no volume  overload  should  be  given  ACE  
inhibitors  [32].  
2.3.2.  ACE  inhibitors  
Besides  their  antihypertensive  features,  they  represent  the  first  line  therapy  in  the  various  
forms of heart failure. ACE inhibitors are the most important pharmaceutical preparations  in the 
long-term treatment of chronic heart failure; they have a favorable effect on functional capacity, 
therefore their use in left ventricular  systolic dysfunction is indispensable.  They are regarded as  
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the cardioprotective  agents of the  1990s as,  apart  from their clinical  use, their preventive effect 
slows  down  the  progression  of  heart  failure  [15,40,58].  No  other  vasodilator  can  produce  a  
similar reduction in heart  frequency [47]. Large-scale, randomized studies prove their efficiency 
in the prevention and treatment of post-infarct circulatory failure [59,60,61,62,63]. 
Several  studies  have  found  that  ACE  inhibitors  considerably  reduce  the  morbidity  and  
mortality  of  patients  suffering  from  heart  failure,  and  at  the  same  time  the  duration  of  
hospitalization  is  shortened.  An  ACE  inhibitor  mortality  study  closed  in  1999  proved  that  
captopril is as efficient as  13 blockers and diuretics in the prevention of cardiovascular  morbidity  
and  mortality  [59,62,64,65].  In  asymptomatic  patients  with  moderate  or  severe  left  ventricular  
systolic dysfunction -  whose ejection fraction is lower than 35-40% - the administration of ACE 
inhibitors reduces the  development  of heart  failure and hospitalization.  Data on mortality  show  
no  difference.  In  symptomatic  heart  failure  the  administration  of  ACE  inhibitors  reduces  
symptoms, hospitalization and mortality  [15,35,65,66,67,68,69,70,71].  
Several  multicenter  trials  -  CONSENSUS,  VHeFT  II,  SOLVD  -  have  considered  the  
favorable effects of ACE inhibitors, especially enalapril  [72,73,74].  
The  HOPE  study  represents  a  new  milestone  in  the  prevention  of  cardiovascular  diseases.  
Ramipril obviously and significantly reduced cardiovascular mortality and the number of infarcts 
and cerebrovascular accidents in the high-risk patients examined  [15,75].  
ACE inhibitors have a considerable  role  in  several  cardiovascular  syndromes but  they  have  
almost revolutionalized the treatment of heart failure. Their significance in the treatment of post-
infarct left ventricular dysfunction and also in diabetic neuropathy is constantly increasing  [76].  
According to the AHCPR guideline, the single use of ACE inhibitors may be  satisfactory in 
patients complaining about exhaustion or exercise dyspnoe, or in case complaints and  symptoms 
of  volume  overload  do  not  occur.  ACE  inhibitors  should  be  combined  with  diuretics  when  
complaints  persist  in  spite  of  pharmaceutical  therapy  or  when  symptoms  of  volume  overload  
develop [32].  
2.3.3.  Cardiac glycosides 
Digitalis glycosides have represented  a well-known  and widely used option in the  treatment  
of  cardiac  failure  for  the  past  200  years;  however,  their  effect  mechanism  has  not  been  
understood  until  recently.  Previously  they  were  praised  because  of  their  positive  inotropic  
effects; nowadays their neurohumoral effects are in the focus of attention. 
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The  DIG-trial,  dealing  with  the  effect  of  digitalis,  found  that  although  it  did  not  modify  
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prognosis  (overall  mortality  and  cardiovascular  mortality),  the  application  of  digitalis  reduced  
morbidity  and hospitalization.  Digitalis involves no safety issues concerning long-term physical  
performance and quality of life  [36,40,77,78,79,80,81].  
In the treatment of chronic heart failure with systolic dysfunction, ACE inhibitors  combined  
with digitalis still represent the basic components of pharmaceutical therapy  [41].  
According to the AHCPR  guideline,  digoxin  should  be  combined  with  ACE inhibitors  and  
diuretics  in  severe  heart  failure.  Frequently,  complaints  caused  by  mild  or  moderate  
decompensation  may be totally relieved by  an optimal  dose of ACE inhibitors  and diuretics;  in  
this case there is no need for digoxin. Digoxin should be used as a supplement when the optimal 
dose ACE inhibitor - diuretic treatment fails to relieve the patient's symptoms [32,41].  
2.3.4.  Anticoagulants  
Patients with heart failure are prone to develop thromboembolic  complications.  
Several  retrospective  studies  have  analyzed  anticoagulant  therapy  in the  treatment  of  heart  
failure  and  according  to  their  findings  the  effect  of  anticoagulants  on  mortality  and  on  the  
development  of  thromboembolism  is  paradoxical,  their  regular  administration  may  not  be  
justified [82,83,84,85].  
According  to  the  AHCPR  study,  the  application  of  a  routine  anticoagulant  therapy  is  not  
indicated.  Provided there  is  systemic  or pulmonary  embolism  or recent  atrial  fibrillation  in the 
history  of  the  patient,  it  is  indicated  to  start  an  anticoagulant  therapy  resulting  in  the  1.2-1.8  
times lengthening of die prothrombin time [32].  
2.3.5.  Other pharmaceutical  preparations  
fi  blockers are applied in order to prevent the activation of the parasympathetic system, which 
plays an important role in the development and progression of heart failure. 
Previously these agents were not indicated in the treatment of circulatory failure due to their 
negative  inotropic effect. Recently  several  studies (CIBIS I., CIBIS II. MERIT-HF  Study) have 
found that  long-term fi  blocker  therapy  in  heart  failure  improves  both  clinical  symptoms  and  
prognosis  [35,40,42,71,86,87,88,89,90,91].  
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Initially,  fl  blocker  therapies  may  have  side  effects;  however,  in  case  of  prolonged  
administration they have the favorable effects of reducing the risk of progression and improving 
survival. Their application is contraindicated in unstable conditions and in NYHA Class IV [40].  
According to the guidelines of the AHCPR, if the dose of ft blockers is increased  gradually,  
they  have  a  positive  long-term  effect on  the  symptoms  of  decompensated  patients  and  on  the  
prognosis of the disease. 
The  physiological  background  to  the  application  of  vasodilators  in  heart  failure  is  the  
reduction  of  cardiac  preload  with  venous  and  afterload  with  arteriolar  dilation.  Nitrates  have  
been used as a medicine for centuries. Drugs with a direct vasodilator  effect can be  alternatives  
to  ACE  inhibitors  [40,44,53].  If  patients  treated  with  an  optimal  dose  of  diuretics,  ACE  
inhibitors  and  digoxin  still  have  resistant  dyspnoe,  ACE  inhibitors  may  be  supplemented  with  
vasodilators.  Drugs  with  a  direct  vasodilator  effect  are  especially  effective  in  hypertensive  
patients.  Nitrates  are  mostly  indicated  in  rational  therapy  if  symptoms  indicate  pulmonary  
congestion;  such  as  orthopnoe,  nocturnal  cough  attacks  and  dyspnoe,  exertion  dyspnoe,  
congestive murmur, dilated jugular veins, or if pulmonary congestion and a reduction in systolic 
blood pressure are dominant in the clinical picture  [32,41].  
Ca channel blockers are popular mostly because of their fast and efficient hypotensive effect; 
however,  the  safety  of  their  long-term  application  has  been  questioned  lately  [42].  First  
generation  Ca  channel  blockers  are  usually  contraindicated  in  heart  failure  with  systolic  
dysfunction  due  to  their  negative  inotropic  and  neurohumoral  activating  effect.  Second  
generation Ca channel blockers -  felodipine, amlodipine -  have practically no negative inotropic 
effects;  they  act  similarly  to  vasodilators.  They  do  not  exacerbate  symptoms  or  increase  
mortality; therefore their application in heart failure seems to be safe [92,93]. 
Heart  failure  is  the  subject  of  a  wide  range  of  cardiovascular  research  -  from  basic  
examinations concerning its pathophysiology to international  studies analyzing the efficiency of 
therapeutic interventions in thousands of patients. 
When  treating  a  patient,  apart  from  features  concerning  etiology  and  severity,  several  
important  factors  should  be  taken  into  consideration,  including  age,  familial  background,  
lifestyle, nature  of  accompanying  diseases,  compliance,  reaction  to  the  pharmaceutical  therapy  
introduced.  On  deciding  which  of  the  above  mentioned  pharmaceutical  preparation^)  we  are  
going to opt for, the significance of these factors is similar to that of the underlying disease. 
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3.  Materials and  methods  
3.1.  Background of the project 
In  1996,  the  Hungarian  Ministry  of  Welfare  initiated  a  project  in  order  to  study  the  
effectiveness  of  implementing  of  practice  guidelines  in  Hungarian  hospitals.  Originally  6  
practice guidelines developed by the AHCPR were introduced in Hungary with the assistance of 
the US Agency for International Development  (USAID).  
The  Major  Department  III  of  the  Hungarian  Ministry  of  Welfare,  and  the  Ministry's  
Consultation  Center  for  Quality  Improvement  in  Health  Care  (EMIKK)  have  had  good  
professional relations  due to previous  successful co-operations,  and the  former as  an  academic  
coordinator,  and the  latter  as  a practical  coordinator  have been  entrusted  with  undertaking  this  
project.  The  Hungarian  Ministry  of  Welfare  initiated  the  survey  named  "BORCSI"  (after  the 
initials  of the  involved hospitals)  in  autumn,  1996, which was planned  originally  for a  span  of  
one year.  This program was meant to  assess the  Hungarian  implementation  and  adaptability  of  
the  guideline  titled  "Heart Failure:  Evaluation  and  Care  of  Patients  with Left-Ventricular 
Systolic Dysfunction" and the direct effects caused by the changes in clinical practice but it does 
not deal with the analysis of the effects on the health conditions of patients. We have joined the 
data collection, verification, data processing and assessment procedure of this guideline. 
The  guidelines  developed  by  the  AHCPR  were  issued  and  introduced  in  Hungary  in  three  
volumes. The first volume outlines the methodology  of guideline development  and the levels of 
familiar  evidences;  its  aim  is  to  make  the  application  of  the  guideline  accepted.  The  second  
volume  gives  a  short  description  of  the  realization  process  of  health  provision  for the  service  
providers. The third volume informs the patients about what happens to them and why it happens 
during receiving health care in order to encourage patient compliance. 
The  financial  support  provided  by  the  Ministry  (HUF  1.5-2  million  for  each  participating  
hospital) was able to cover the cost of translating the practice guideline developed for informing 
doctors  (service  providers)  and  patients  into  Hungarian,  and  the  cost  of  organizing  and  
accomplishing data collection in the hospitals i.e. they provided the financial  background  of the 
Hungarian implementation of this practice guideline. 
The trial of this practice guideline was performed in six Hungarian institutions (H1-H6).  The 
certain levels  of Hungarian  inpatient  health  care  could be represented  by  initiating  3  municipal  
hospitals,  1  county  hospital,  1  university  teaching  hospital  and  1  national  institute  in  this  
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program.  (These  institutions  will  be  mentioned  further  in  the  text  as  hospitals,  institutes  or  
institutions regardless of their real status.) 
The  academic  coordinator  was  to  make  a  recommendation  on  the  basis  of  the  number  of  
cases  as  to  the  assignation  of  "sample  departments"  in  those  institutes  that  volunteered  to  
disseminate the uniform practice  guideline. Local coordinators responsible for the project  (head 
physicians  or medical  specialists)  were  assigned  in the institutions.  These program leaders had 
the  appropriate  level  of  authority  to  make  decisions  and  to  ask  for  reports,  and  their  
responsibility was to be in constant  communication  with the academic  coordinator  (Ministry  of  
Welfare)  and  the  practical  coordinator  (EMIKK).  Their  task  included  the  co-ordination  and  
controlling  of the project within their institute, the local distribution  of tasks, the assignment  of  
people who took part in the accomplishment  of these tasks, and they had to take part personally 
in the quarterly meetings and to report on the  local  experience.  The organization  of the project 
i.e.  detailed  planning  of  the  survey,  central  data  collection  and  assessment  of  results  was  
accomplished by EMIKK. 
3.2.  Main steps of the project 
3.2.1.  Preparation of the project 
In  June  1997,  the  representatives  of  the  hospitals  participating  in  the  program  were  
summoned to the Ministry of Welfare in order to hold an expert forum and to  give information 
about  the  program.  Leading  specialists  of  this  special  field,  local  coordinators  of the  involved  
institutes,  representatives  of  the  EMIKK  and  Ph.D.  students,  who  did  data  processing  and  
assessment work, took part in the meeting. The aim of this meeting was to compare the  aspects  
of the guideline with the Hungarian  conditions, to adapt these guidelines, to determine  whether  
the  guideline  contained  recommendations  the  implementation  of  which  cannot  be  resolved  
within the Hungarian circumstances and to be able to prevent in time the incidental problems that 
may arise. 
The  institutions  received  the  Hungarian  translation  of  the  guideline  adapted  to  Hungarian  
conditions  but  the  Ministry  of  Welfare  did  not  regulate  the  process  how  the  guideline  was  
introduced  and put  into everyday practice,  this task was complemented  locally  in the  sphere of  
authority  of  the  individual  institutions  taking  the  local  conditions  and  facilities  into  
consideration.  The  assigned  local  coordinators  were  informed  about  the  schedule  and  the  
accomplishable tasks of the project beforehand. 
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3.2.2.  Selection of data for  data collection 
At the planning of data collection, the following aspects had to be considered: 
-  Is it possible to trace the group of patients with this particular diagnosis category? 
-  How has the examination and treatment of this disease been documented? 
-  Is  it  possible  to  make  a  distinction  between  the  documentation  of  this  particular  
disease and that of other illnesses in case of individual patients? 
Further important aspects included: 
-  the ability to observe clinical practice, 
-  the exact determination of the time limit of the survey, 
-  the consultation with the coordinators as to the method of data collection, 
-  the  realization  of  data  collection  (the  assignment  of  the  leaders  of this  task  and  the  
organization of external and internal control). 
Collectable data included the following fields: 
-  demographic characteristics of the patient, 
-  duration and scene of hospital care (hospital  admission/discharge),  
-  required nursing, 
-  initial diagnoses/other  illnesses,  
-  anamnestic data (complaints, previous medication, former hospital treatment,  surgical  
interventions), 
-  parameters of physical  status,  
-  examinations during hospital stay: 
- laboratory tests, 
- imaging procedures, 
- treatments,  interventions.  
-  medicinal therapy applied during inpatient hospital stay. 
3.2.3.  Planning data collection, scheduling the study 
In  order  to  examine  the  effects of  the  practice  guideline,  the  method  of  the  'before-after'  
epidemiological  study was used, which had been preceded by a quite detailed pilot study. 
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3.2.3.1. Pilot study 
The first phase of data collection was to design a data sheet in order to be able to observe the 
practice  of  hospital  care.  Before  starting  the  actual  study  these  data  sheets  were  sent  to  the  
institutions for testing  in  order to  find the  final  form. The participants  filled  in the  data  sheets  
retrospectively  about their patients, to whom they previously provided care, on the basis of their 
documentation, the case-history sheets, according to the instructions concerning filling in. 
In the course of the pilot  study we visited  all the  scenes  concerned,  and personally  checked  
the  validity  of  the  data  indicated  on  the  data  sheets  filled  in  in  the  various  institutions  by  
comparing  them  against  the  case-history  sheets  and  other  related  documents  (bedhead  boards,  
nursing  documentation,  laboratory  findings,  final  reports,  etc.).  During  the  pilot  study  65  data  
sheets of 5 hospitals were checked. The validity of data collection concerning the introduction of 
the practice guideline was monitored by observing the completeness and appropriateness of data. 
For  the  assessment  and  objectivity  of  the  information  on the  data  sheets,  we  constructed  two  
indices,  which were used  later  as well.  The extent  to  which the project  could  be  followed was 
characterized  by the  "availability  index",  which  indicated the  availability  of the  information in  
the basic documentations needed for accomplishing the study. The "reliability  index" referred to 
the filled in data sheets, which were qualified according to the following criteria: 
1.  fully correct group of questions 
2.  incomplete filling in but data can be found in source documentation 
3.  incorrect piece of data, not in accord with the case-history sheet 
4.  incomplete filling in, data cannot be found in the case-history sheet either 
5.  the piece of data cannot be found in the case-history sheet but the question was answered 
(source of information is unknown)  [14].  
We  gave  an  account  of  the  findings  of  the  pilot  study  at  a  ministry  meeting.  Detailed  
description  of  our  conclusions  was  presented  to  the  individual  data  providing  institutions  
respectively.  We  suggested that  the  local  coordinators  should  acquaint  the  colleagues  with  the  
problems that arose, especially those colleagues who work in these particular problematic fields.  
Another  suggestion  was  that  hospital  administrators  should  fill  in  these  data  sheets  if  possible  
since they  could  accomplish this task  correctly  and meticulously,  as they  previously  proved  it,  
and that it is necessary for them to receive assistance from physicians [14]. 
The  findings  of  the  pilot  study  revealed  that  the  documentation  principle  considerably  
improved  at  the  departments  concerned,  the  assessment  of  the  data  sheets  became  easier  and  
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their completeness increased. This change is the first, and in our opinion the most important  step  
in the quality improvement of the institutions. 
3.2.3.2. The  'before-after'study  
The actual  examination was carried out by the  'before-after9 epidemiological  study  method.  
In  the  course  of  this  examination  we  studied  the  health  care  practice  before  and  after  the  
dissemination  of  the  guideline  on  the  basis  of  health  care  documentation  provided  by  the  
institutions.  We  examined  whether  the  introduction  of the  guideline  had  any  impact  on  health  
care practice in the given institutions,  and if it had we wanted to know how and to what  extent  
the  care, treatment  and medicinal  therapy  of patients  with  heart  failure in  inpatient  institutions  
had changed. 
The  existing  medical  files made  it  possible  for us  to  compare  the  collected  data  after the 
dissemination of the guideline with the documentation of patients provided before the adaptation 
of the guideline within the institutions respectively in order to be able to observe the effects. The 
collection  of examination  and  control  data was  carried out  simultaneously,  in the period before 
the  dissemination  of  the  guideline  it  was  done  retrospectively  and  in  the  period  after  the  
dissemination of the guideline, prospectively. 
The  data  sheet  used  for  data  collection  acquired  its  final  form  after  implementing  the  
corrections  deemed  necessary  on  the  basis  of  the  findings  of  the  pilot  study.  The  data  sheets  
together with the guidelines adapted to the Hungarian conditions were sent to the institutions in 
January  1998.  
The actual examination can be divided into the following periods on the basis of the time of 
hospital admission: 
'before' (B) ~ retrospective period'. 1 January  1997 -  28 February  1998, a period for 
studying the prevailing conditions: when the existing practical care was studied; 
'after' (A) ~ prospective  period'.  15 March  1998 -  15 March  1999; data provided  in  
this  period  reflected  on  patient  care  of  chronic  heart  failure  after  the  institutions  
participating  in  the  project  had  become  familiar  with  the  recommendations  of  the  
evidence-based practice guideline. 
By the  prospective  period  of  data providing  the  physicians  and  the  specialized  staff  of  the  
hospital departments had got to know the practice guideline and the instructions for filling in the 
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data  sheets  in  a  uniform  manner.  The  assigned  program  leaders  in  the  inpatient  institutions  
carried out the technical co-ordination of the project. 
In both examination  phases,  data providing  concerned those patients  who were  admitted  to  
these particular inpatient institutions in the periods indicated  above, with the initial diagnosis of 
chronic heart failure according to the ICD-10  [150] or with any initial  diseases that may lead to 
heart failure such as arteriosclerotic heart disease -  [120-125], hypertensive heart disease -  [110-
II1,113], valvular heart disease -  [134-135], or dilatative cardiomyopathy  [142]. All patients were 
represented in the program who had chronic heart failure regardless of the fact that their hospital 
admission was or was not the result of this particular condition. 
With respect to the applied medication, the data collection included not only those drugs that 
were normally used in the management  of chronic heart failure but all types of drugs that  were  
prescribed  during  the  hospitalization  period.  Since  the  practice  guideline  developed  by  the  
AHCPR recommends the use of diuretics, ACE inhibitors, cardiac glycosides and anticoagulants  
as the initial phase in medicinal treatment, primarily the analysis of these groups of drugs will be 
presented. 
The data sheets  contained  information on the name of the  drug applied  during the  inpatient  
hospital  stay,  its daily dosage,  and the period  of the therapy. The registration  of the potency  of  
drugs and the form of their packaging was not very precise. 
We  completed  the  categorization  of the  applied  drugs  according to  the  active  agent  on the 
basis of the Anatomical, Therapeutic, Chemical classification of drugs (ATC-code). 
3.2.4.  Processing and analyzing data 
In the  course  of the  entire  research period,  checking the validity  of  data was  carried  out  at  
random. The coding and computerizing of data sheets filled in by the institutions were performed 
continuously. Processing and analyzing data with the help of a statistical program,  SPSS 9.0 for 
Windows,  could  only be  started  after  15 March  1999.  The  statistical  tests  were  accomplished  
with the help of Pearson's  chi-squared test and the Mann-Whitney U test.  The significance level 
was p<0.05. Examinations with more than one variable were carried out by logistic regression as 
a possible statistical modeling form. During the piloting the H4 county hospital was chosen as a 
reference hospital with regard to its intermediary position in progressive patient care. 
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4.  Results  
In the first part  of this section following the structure of the data sheet the  socio-demographic  
parameters  of the  surveyed  population  and the  major patient  state  variables  assessed  before  and  
at the time of hospital admission are presented  comparing  the observed  'before-after'  phases.  
In the course of the 'before-after' epidemiological  study a total of  1386 data sheets have been 
filled  in by the 6 hospitals.  Finally, data of  1222 patients met the requirements.  46.3  % (566)  and  
53.7  %  (656)  of  these  patients  constituted  the  database  of  the  period  before  and  after  the  
dissemination of the guideline  respectively.  
4.1.  Socio-demographic  features  
According  to  the  socio-demographic  parameters  shown  in  Table  1  48.9  %  of  the  1222  
patients  were  male  and  51.1  %  was  female.  In  the  before period  the  sexes  were  represented  in  
50.0-50.0 % but in the after period the proportion of women is slightly higher (52.0 %).  
The average  age was 67.3±12 years; the youngest patient was 22 and the oldest,  97. 
Table  1  Major socio-demographic  features of the patients  in the 'before'  and  'after'  periods  
Investigation  periods  
Characteristics 
Before After Altogether 
Sex 
Male  (%)  50.0 48.0 48.9 
Female  (%)  50.0 52.0 51.1 
Age/mean  ± SD/  (yr)  67.1  +  12.0  67.4  +  12.0  67.3  +  12.0  
Age 
groups 
< 65  yr(%)  36.9 36.3 36.6 
65-75 yr (%) 36.1 34.1 35.0 
> 75  yr(%)  27.0 29.6 28.4 
Family 
background 
Single  (%)  16.2 16.5 16.4 
In family (%) 83.8 83.5 83.6 
From  an epidemiological  point  of view, the  age groups  are very  significant  and  in  patients  
with  heart  failure  the  age  groups  showed  the  following  facts:  nearly  one-third  of  all  patients  
(36.6 %) was under  65,  and two-thirds  of all patients  (63.4  %) were  over  65.  With  respect  to the 
cardiovascular  diseases we have to lay emphasis  on the fact that 28.4 % of all  patients were  over  
75. The proportions  in the 'before-after' study periods did not change much. 
The  breakdown  by family  background  showed  that  83.6  %  of  the  patients  lived  with  their  
families and only  16.4 % lived on their  own.  
As  far  as  socio-demographic  parameters  are  concerned  there  was  no  statistically  significant  
difference between the two study periods.  
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4.2.  The period before hospital  admission  
Table  2  shows the  hospitalization  indicators  of  patients,  almost  half  of  them  (49.3  %)  were  
admitted  as  emergency  cases.  In the period  after the  dissemination  of the  guideline,  the  number  
of  patients  admitted  as  emergency  cases  significantly  increased  and  the  number  of  planned  
patient admissions  decreased.  
Table  2  Major  hospitalization  indicators  in the  'before'  and  'after'  periods  
~~~~—^^  Investigation  periods  
Characteristics  •  
Before After Altogether 
Admission 
state  *  
Urgent  (%)  42.1 56.4 49.3 
Non-urgent  (%)  57.9 43.6 50.7 
Nursing 
need 
Bedridden(%) 24.8 24.2 24.5 
Self-catering (%) 75.2 75.8 75.5 
Average  nursing time /mean±SD/  (day) * 10.8 ±7 .9 8.6 ±5 .9 9.6  ±7 .1 
*  p<0.05  (in the  'before'  and  'after'  period)  
As for  required  nursing,  almost  three  quarters  of  all  patients  did  not  need  nursing  in  either  
period. 
The  average  number  of  days  when  nursing  was  required  9.6;  after the  dissemination  of  the  
guideline  this  number  dropped  from  10.8  days  to  8.6  days,  thus  a  significant  change  was  
experienced.  The  shortest  period  spent  in  the  inpatient  institution  in  the  'before-after'  periods  
was  1 day in both periods, and the longest  stay was  82 and 64 days respectively.  
40.1 % of all patients were admitted with the  initial  diagnosis  of chronic heart  failure  [150], a 
considerable  proportion  of patients  were  admitted  with the  initial  diagnosis  of  chronic  ischemic  
heart  disease  [125]  (23.8  %),  dilatative  cardiomyopathy  [142]  (10.6  %),  hypertensive  heart  
disease  [111]  (9.0  %)  and  hypertension  [110]  (4.0  %),  and  12.5  %  of  all  patients  was  admitted  
with other initial  diagnoses.  
As  Figure  1  demonstrates,  in  the  period  after  the  dissemination  of  the  guideline  the  
proportion  of  patients  admitted  with  the  initial  diagnosis  of  heart  failure  significantly  increased  
(B: 35.9  %, A: 43.8  %). At the  same time the proportion  of patients  with  the  initial  diagnosis  of  
hypertension  (B:  4.4  %,  A:  3.7  %),  chronic  ischemic  heart  disease  (B:  26.5  %,  A:  21.5  %),  
dilatative  cardiomyopathy  (B:  11.5%,  A:  9.9  %)  decreased,  the  degree  of  the  change  in  case  of  
the latter ones cannot be assessed  statistically.  
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•  111  (Hypertensive  
cardiac  disease)  
—  125 (Chronic  ischaemic  
heart  disease)  
•  142 (Dilatative  
cardiomyopathy) 
- 1 5 0  (Heart  failure)*  
'  Other initial diagnoses 
Before After 
* p<0.05  (in the  'before'  and  'after'  period)  
Figure  1  Initial  diagnoses  of patients  admitted  in the  'before'  and  'after'  periods  
The number of other  diagnoses  was an average of 6.1 ±2.7. There were patients with no other 
illnesses  besides  the  initial  diagnosis,  but  sometimes  the  number  of  other  diagnoses  was  almost  
twenty. 
The examination  of patient  complaints  comprised  the existance of dyspnoea  (88.8 %),  edema 
(67.6 %), angina (56.1 %), headache  (19.1 %) and arrhythmia (49.4 %).  
•A 
90-
Dyspnoea Edema Angina Headache  Arrhythmia  
* p<0.05  (in each  period)  
Figure  2  Frequency  of complaints  in the  periods  before and  after the  dissemination  of the  guideline  
20 
Figure  2  clearly  shows  that  comparing  the  'before-after'  periods,  significant  difference  
occurred only in case of angina complaints; there was no considerable change  in the frequency of 
other  symptoms.  The  most  frequent complaints  among  patients  were  dyspnoea  and  edema.  The  
occurrence  of  arrhythmia  complaints  decreased  in  the  'after'  period,  and  in  case  of  the  other  
complaints there was a slight rise in numbers. 
It  is worth  having  a  look  at  one  of the  anamnestic  data,  the patients'  smoking  habits:  on  the  
one  hand  three  quarters  of  them  (B:  76.0  %, A:  75.5  %)  have  never  smoked,  on the  other  hand  
15.0 % and  11.4 % of the patients, respectively,  smoked during their existing disease as well. 
Figure  3  demonstrates  the  main  features  of  prescription  in  case  of  drugs  that  affect  the  
cardiovascular  system  in  the  period  before  hospital  admission.  The  applied  drugs  were  
categorized as follows: 
-  drugs  listed  in  the  recommendation  of  the  practice  guideline  (diuretics,  ACE  
inhibitors, cardiac glycosides,  anticoagulants),  
frequently used cardiovascular  drugs but not mentioned  in the recommendation  of the 
practice guideline (beta blockers,  nitrates),  
-  other drugs affecting the circulatory  system.  
Ca channel  blockers  
Vasodilators 
Antihypertensives 
Antiarrhythmics 
Nitrates 
ß  blockers  
Anticoagulants 
Cardiac  glycosides  
ACE  inhibitors  
Diuretics 
Drug  groups  
<x 
Figure  3  Frequency  of drug  application  before admitted  to  inpatient  institutions  (%)  
Every  second  patient  (52.0  %)  received  diuretic  treatment;  41.3  %  of  the  patients  received  
one type of diuretics,  9.8 % got two different types and  in case of 0.9 % of all patients more than 
two  types  of  diuretics  were  prescribed  simultaneously.  The  most  frequently  used  active  agents  
were  furosemide (38.4  %)  and  the  hydrochlorothiazide+potassium-retentive  diuretics  /HCT+K-
sparing/  (14.5  %)  but  the  use  of  chlopamide  (4.2  %)  and  spironolactone  (4.4  %)  was  also  
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common. At the  same time drugs containing thiazide  (0.3  %)  and K-cancreonate  (0.2 %)  were  
practically not prescribed. 
48.2  %  of  all  patients  received  ACE  inhibitors.  The  use  of  one  particular  type  of  ACE  
inhibitor was predominant; only 0.6 % took two types of drugs simultaneously. Enalapril (28.0 %) 
and captopril (13.1 %) were the most popular and most frequently prescribed ACE inhibitors but 
the use of perindopril  (4.4 %) cannot be neglected  either.  The other drugs within this  particular  
group were not dominant; their frequency was under  1 %. 
Cardiac glycosides  were prescribed  in case  of  27.7  % of  all patients;  basically  one type  of  
drug was favored. The leading drug in this group was digoxin (26.1 %). 
Anticoagulants were applied in case of one third of all patients (36.1 %) in the period before 
admission.  4.4  %  of  all  patients  received  two  or  more  drugs  simultaneously.  In  this  group  of  
drugs  the  prescription  of  acenocumarol  (19.4  %)  and  acetylsalicylic  acid  (18.3  %)  was  
predominant. 
P blockers were  prescribed  in  case  of  26.2  %  of  all  patients.  Mainly  drugs  with  the  active  
agents of metoprolol (19.5 %), bisoprolol (2.8 %) and atenolol (1.7 %) were used. 
Organic nitrates  were  the  most  favored  drugs  in  the  period  before  admission  to  inpatient  
institutions:  57.7 % of all patients received them and 2.2 % took two types of them at the  same  
time.  Nitroglycerin  (43.0  %)  and  isosorbide-mononitrate  (16.0  %)  are  heading  the  list;  the  
prescription  of  isosorbide-dinitrate  (0.3  %)  and  pentaeritril-tetranitrate  (0.6  %)  was  not  
significant. 
As for other cardiovascular drugs, Ca channel blocking agents were taken by 22.6 % of  all  
patients. 
4.3.  Determination of physical condition of patients at time of hospital admission 
The following parameters  were taken  into consideration  when  assessing the physical  status  
of patients suffering from heart failure: edema was observed in 56.1 % of all patients  (primarily  
in  the  form  of  crural  edema),  15.3  %  were  cyanotic,  66.5  %  had  cardiomegaly,  12.0  %  had  
pulmonary edema, 60.4 % had  rhoncus, 56.4  % had  chronic liver  enlargement, and  3.7 % had 
ascites. 
Figure  4  shows  the  patients  participating  in  the  project  according  to  these  physical  status  
parameters in the 'before-after' periods. 
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The  proportion  of  patients  with  enlarged  hearts  in  one  or  both  directions  increased  
significantly in the period after the dissemination  of the guideline (B: 65.2  %, A:  72.0 %).  At the 
same time the proportion of patients admitted with chronic liver enlargement  decreased (B: 60.9 %, 
A:  52.6 %). Both changes have to be considered significant.  
* p<0.05  (in each  period)  
Figure  4  Parameters  of  physical  status  in the  'before'  and  'after'  periods  
At  hospital  admission  the patients  were  categorized  according  to  the  NYHA  classification:  
8.6 % of all patients  belonged to NYHA  I, 20.3 % to NYHA  II, 31.1% to NYHA  III  and 40.0  % 
to  NYHA  IV.  Figure  5  demonstrates  the  NYHA  classification  at  the  time  of  admission  in  the  
observed  periods.  
% 
45-i 
B  Before  
0  After  
NYHA  I  NYHA  II  NYHA  III 
Figure  5  NYHA  classes  of patients  at the time of  hospital  admission  in the  'before'  and  'after'  periods  
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In  both  periods  most  patients  were  admitted  with  NYHA  IV.  The  proportion  of  patients  
belonging to NYHA  II  and  III  increased  in the  period  after the  dissemination  of  the  guideline  
(NYHA II -  B:  18.5 %, A: 21.9 %; NYHA III -  B: 30.6 %, A: 31.5 %). At the same time fewer 
patients were admitted with having NYHA I  (B:  10.3 %, A:  7.1 %) and NYHA IV (B: 40.6  %,  
A: 39.4 %) in the after period. The change was not significant in either case. 
4.4.  Description of the pharmaceutical therapy of patients with chronic heart failure 
The  AHCPR  guideline  recommends  the  application  of  diuretics,  ACE  inhibitors,  cardiac  
glycosides  and  anticoagulants  in the  introductory  phase  of  heart  failure treatment.  This  part  of  
the study will cover the use of the above-mentioned pharmaceutical preparations before and after 
the dissemination of this guideline. 
4.4.1.  Diuretics  
Out of the 82.6 % of patients who received diuretics,  50.8 % received one, 25.3 % two and  
6.5 % three or more different types of diuretics  simultaneously.  17.4 % of patients treated  with  
chronic heart failure received no diuretics. 
Before the dissemination  of the AHCPR guideline,  81.4 %, after 83.5  % of the patients  got  
diuretics. 
As illustrated  in Figure 6, the most frequently used diuretics were preparations  containing  a  
combination  of  furosemide  (69.5  %)  and  (HCT)  +  K-retaining  diuretic  agents  (27.9  %).  
Spironolactone  (7.7  %)  and  ethacrynic  acid  (6.6  %) were  less  frequently  used.  Thiazides  were  
practically  unused  in  diuretic  therapy  (0.2  %)  and preparations  containing  clopamide  (3.6  %),  
chlorthalidone (2.6 %) and K-cancreonate were also seldomly applied [94].  
After  the  dissemination  of  the  AHCPR  guideline,  the  use  of  preparations  containing  
clopamide,  chlorthalidone,  ethacrynic  acid  and  K-cancreonate  was  reduced;  the  reduction  was  
most significant in case of ethacrynic acid. At the same time, furosemide and HCT + K-retaining 
diuretic agents were used in more patients. The increase in the number of diuretic treatment was 
due to the more frequent application of the two latter agents. 
There were significant differences in the duration of application  between the different types 
of  diuretics.  Clopamide,  chlorthalidone  and  spironolactone  were  used  longest;  on  the  average  
they were used for  10.0,  9.3,  9.2  days, respectively  (minimum  1 -  maximum  27, 41,  22  days).  
The average duration of application in case of the most rarely used K-cancreonate was 5.5 days 
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(minimum  3 -  maximum  11).  After the  dissemination  of the  AHCPR  guideline,  the  duration  of  
application of all diuretics shortened except for chlorthalidone. 
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Figure  6  The frequency  of diuretics  (%)  and  the average  duration  
of their  application  (days)  in the  'before'  and  'after'  periods  
Very  short,  one  or  two-day  therapies  for  chronic  heart  failure  mostly  occurred  due  to  the  
death  of  hospitalized  patients;  however,  there  were  some  cases  of  relatively  longer  
hospitalization  with short-term medication, the therapeutic benefit of which may be  questioned.  
4.4.2.  A CE inh ibitors 
68.0  %  of  patients  hospitalized  with  chronic  heart  failure  received  ACE  inhibitors  and  in  
most  of the  cases  (65.2  %) these preparations  were  not  combined  with  anything  else.  However,  
32.0  %  of  patients  received  no  ACE  inhibitors.  Before  the  dissemination  of  the  AHCPR  
guideline,  64.7 % of patients with heart failure received ACE inhibitors, this number  rose to  70.9 % 
in the 'after' period. The rate of increase is significant. 
As  illustrated  in  Figure  7,  from  all  the  ACE  inhibitors  registered  and  sold  in  Hungary,  
enalapril  (44.4  %),  captopril  (12.7 %)  and perindopril  (6.9  %) were  used  in most  ACE  inhibitor  
therapies. 
When considering  the  'before'  and  'after'  periods,  we  can conclude  that  the  use  of  captopril  
significantly decreased, resulting in the statistically increased use of enalapril  and perindopril  [94].  
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Regarding the duration of application  of ACE inhibitors,  all preparations except for cilazapril 
were used shorter after the dissemination  of the guideline.  Preparations containing  lisinopril  were  
used the longest ('before'  14.7, 'after'  11.8 days)  [95].  
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Figure  7  The frequency  of ACE  inhibitors  (%)  and  the average  duration  
of their  application  (days)  in the  'before'  and  'after'  periods  
According  to the AHCPR  guideline,  the excessive  use  of diuretics  should  be  avoided  before  
the application  of ACE inhibitors.  If symptoms persist  in spite of the ACE inhibitor therapy, or if  
symptoms of volume overload occur, the treatment should be supplemented  with  diuretics.  
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Figure  8  The  order  of applying ACE  inhibitors  and  diuretics  in the 'before'  and  'after'  periods  
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Figure  8 illustrates the results of examining the time passed before the institution of  diuretic  
and ACE inhibitor therapy. 
ACE  inhibitors  were  given  prior to  diuretics  only  in  5.0  %  of  all  cases.  The  simultaneous  
application  of  both  types  of  preparations  dominated  in  the  'before'  as  well  as  in  the  'after'  
periods ('before' 41.7 %, 'after' 48.0 %). Monotherapy using only ACE inhibitors ('before' 11.1 %, 
'after'  11.2 %) or diuretics ('before' 27.0 %, 'after' 23.3 %) was also frequent [94]. 
4.4.3.  Cardiac glycosides 
About half of the patients (47.2 %) received a cardiac glycoside monotherapy, while  52.8 % 
of the patients received no cardiac glycosides at all. 
The  application  of  these  preparations  was  reduced  after the  dissemination  of  the  guideline  
('before' 48.9 %, 'after' 45.7 %). 
Almost half of the patients (45.5 %) received digoxin. The use of digitoxin doubled after the 
dissemination  of the  guideline,  still  no more than 2  % of the patients  received  this  preparation  
[94]. 
The  average  duration  of  the  dominant  digoxin  application  was  reduced  after  the  
dissemination  of  the  guideline  ('before'  11,  'after'  9.2  days).  Continuous  application  and  the  
practice of missing two days weekly were both characteristic in the use of glycosides. 
Dissemination  of  the  guideline  did  not  influence  significantly  the  application  of  these  
preparations,  i.  e.  no  active  agents  of  glycoside  showed  a  considerable  difference between  the  
two periods of the examination. 
4.4.4.  Anticoagulants  
Out of the 55.6 % of patients who received anticoagulants,  40.5 % received one,  12.2 % two 
and 2.9 % three or more different types of anticoagulants  simultaneously.  
The  'before'  and  'after'  phases  show  a  significant  difference regarding  the  application  of  
anticoagulants.  Before the  dissemination  of  the  guideline  59.4  %  of  patients  was  treated  with  
anticoagulants, their percentage dropped to 52.5 % in the 'after' period. 
As illustrated in Figure 9, the most frequently used anticoagulant agents were acenocoumarol 
(27.7 %), heparin (8.5 %) and acetylsalicylic acid (28.7 %)[94]. 
All anticoagulants were used less frequently in the 'after' period; however, the reduction was 
significant only in the case of heparin. 
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The average duration  of application was longest  with acenocoumarol  and  acetylsalicylic  acid  
('before'  10.9, 'after'  9.4 days);  however,  there was  a significant variation  in the  actual  duration  
(minimum 2 days, maximum 65 days). 
Except for Na-pentosan-polysulfate,  all anticoagulant  preparations were used shorter after the 
dissemination  of the  guideline.  
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Figure  9  The frequency  of anticoagulants  (%) and  the average  duration  of  
their  application  (days)  in the  'before'  and  'after'  phase  
4.4.5.  Other pharmaceutical  preparations  
Even though the guideline  do not directly  deal with the administration o f f i  blockers,  organic  
nitrates  and  Ca  channel  blockers,  a  short  description  of  their  application  is  important,  partly  
because  they  represent  a relatively  high  proportion  in the  therapy  of  cardiac  failure both  before  
hospitalization  and  in  the  'before  -  after'  periods  and  partly  because,  as  a  result  of  recent  
findings, B blockers have been applied more frequently in the hospital  setting as well. 
32.0 % of patients received fi blockers,  and 31.8 % of them received a monotherapy. 
As  illustrated  in  Figure  10,  26.1  %  of patients  with  heart  failure was  given  metoprolol,  and  
bisoprolol  was  used  in  3.2  %  of  all  cases.  After the  dissemination  of  the  guideline,  both  active  
agents were used more frequently. 
Of  all  fi  blockers,  atenolol  was  used  longest,  which  can  be  attributed  to  the  low  number  of  
cases  ('before'  6,  'after'  6  patients)  and  also  to  the  maximum  indication  of  32  days  in  the  
'before'  period.  
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Figure  10  The frequency of  B blockers  and  nitrates (%)  and  the average  duration  of  
their application  (days)  in the  'before'  and  'after'  periods  
The use of organic  nitrate preparations  was second  only to the application  of diuretics  in the 
treatment  of  chronic  heart  failure.  Out  of  the  71.8  %  of  patients  who  were  given  these  
preparations,  64.3 % received one, 7.5 % two different types of nitrates.  
Nitroglycerin  was applied in 53.1  % of the cases,  and 24.4 % of patients received  isosorbide-
mononitrate  (ISMN).  The  application  of  the  former  agent  decreased,  that  of  the  latter  one  
increased  in the 'after' period, but the rate of difference is not significant in a statistically.  
Preparations  containing  ISMN  were  applied  longer.  The  duration  of  application  of  both  
active  agents  became  shorter  after  the  dissemination  of  the  guideline;  it  varied  between  the  
minimum of  1 and the maximum of 47  days. 
Ca channel  blockers  were  used  in 26.9  % of the  cases.  Significantly fewer patients  received  
such preparations for a significantly shorter time ('before'  32.2 %, 'after' 22.4 %).  
Summarizing  the  comparative  results  of  the  'before'  and  'after'  periods,  the  following  
conclusions  can be drawn: 
The  patient  population  of  the  two  examination  periods  can  be  considered  homogenous  
regarding the most important sociodemographic  parameters.  
-  The  admission  status  showed  a  significant  difference  between  the  two  examination  
periods. 
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The  average  duration  of  hospital  stay  significantly  decreased  after  the  dissemination  of  
the  guideline.  
The  percentage  of  patients  hospitalized  with  the  initial  diagnosis  of  heart  failure  
significantly increased  in the 'after'  period.  
Nitrates,  diuretics  and  ACE  inhibitors  played  the  most  important  role  in  the  
pharmaceutical  treatment  preceding  hospitalization.  Anticoagulants,  cardiac  glycosides,  
B blockers and Ca channel blockers were also frequently applied. 
The parameters  of physical  status recorded  on admission  showed  a significant difference 
between  the  two  examination  periods  in  terms  of  patients  admitted  with  cardio-  or  
hepatomegaly. 
NYHA  classification  on  admission  showed  no  significant  difference  between  the  two  
examination  periods.  
Regarding  the  application  of  the  ATC  groups  highly  indicated  in  the  pharmaceutical  
treatment  of  heart  failure  (see  Figure  11),  dissemination  of  the  guideline  led  to  a  
statistically  meaningful  difference  in  the  application  of  ACE  inhibitors  and  
anticoagulants.  Comparisons  between  the two  examination  periods  reveal  that  the  use  of  
ACE  inhibitors  increased  and  the  application  of  anticoagulants  decreased  by  the  'after'  
period. The shift in the use of these two preparations  complies with the  recommendations  
of the guideline  [94,95].  
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Figure  II  Frequency  of the  most  important  groups  of pharmaceutical  preparations  
recommended  by the guideline (%)  in the  'before'  and  'after'  hospitalization  periods  
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-  The more frequent use of diuretics in the 'after' period can be attributed to the increased 
application of furosemide and HCT+K-sparing diuretics.  
-  After  dissemination  of  the  guideline,  the  use  of  digoxin  was  reduced  but  the  rate  of  
decrease may not be considered significant. 
-  Regarding the use of other preparations that were not directly dealt with in the  guideline,  
the use of B blockers increased in the 'after' period, although not significantly. 
-  The use of nitrates in the pharmaceutical treatment of chronic heart failure was second to 
that of diuretics in both examination periods. 
-  In the 'after' period the use of Ca channel blockers decreased significantly. 
-  The average duration of application in case of all active agents studied was reduced after 
dissemination of the guideline. 
-  The  AHCPR  guideline  recommends  the  initial  use  of  ACE  inhibitors  before  the  
institution of a diuretic therapy.  According to  our  findings,  these two preparations  were  
given simultaneously  in the everyday nursing practice; the  initial  use  of ACE  inhibitors  
alone did not dominate in either examination period. 
How can we evaluate the effect of the guideline on the basis of our findings? 
Analyzing the general practice of medication in chronic heart failure applied by the hospitals 
involved  in  this  study  we  can  conclude  that  it  complies  with  the  recommendations  of  the  
evidence-based guideline; therefore we cannot report on a significant change in medication after 
dissemination  of  the  guideline.  In  the  case  of  ACE  inhibitors  and  anticoagulants  there  was  a  
statistically  meaningful difference between  the two  examination  periods  -  but  the  direction  of  
this change was parallel with the recommendations  of the guideline.  However, when  evaluating  
such  an  impact  study  we  should  not  disregard  traditions  determining  the  various  fields  of  
medicine, whose  influencing or alteration  may only be  executed  over  a longer period  of time  -
namely a couple of years - especially  if the consideration of scientific evidence in the  everyday  
nursing is not required. 
It is difficult to take an unambiguous position when evaluating the comparative, 'before'  and 
'after' effect of the guideline based on the findings discussed above. Therefore, in the following 
we are going to present some parameters that may have influenced the outcome of study. 
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4.5.  The institution-specific characteristics  of the study 
In this section we aim to analyze the inequalities present  in the various fields of medicine  and  
also  in  the  health  status  of  the  general  population  in  different  regions.  The  location  of  the  6  
hospitals  involved  in  this  study  is  rather  heterogeneous,  so  we  have  to  determine  whether  they  
can  be  treated  as  a homogenous  unit  or  whether  there  exist  some  basic  nursing  differences that 
would influence the findings of this project. 
Apart  from  the  period-oriented  examination  aspects  presented  before,  the  consideration  of  
some  institutional  parameters  seems to  be vital  in  order to be  able to  decide whether  the  change  
in the medication practice  of patients treated with chronic heart  failure can really be attributed  to  
the influence of the dissemination  of the  guideline  (as  supposed  earlier)  or  whether  it  is also  the  
result  of  the  different patient  population  and  theoretical  as  well  as therapeutical  attitudes  in  the  
different hospitals  [95],  
4.5.1.  The  most  important  socio-demographic  parameters  
According  to  Table  3 the  distribution  of  sexes  was  closest  to  that  in  the  general  population  
(M: 48.9 %, F: 51.1 %) in institutions H5 (M: 47.4 %, F:  52.6 %)  and H6 (M: 49.5  %, F:  50.5  %).  
The most  striking divergence occurred  in the case of H2. 
Table  3  The  institutional  distribution  of the  most  important  socio-demographic  indices  
Institutions 
Characteristics 
HI H2 113 H4 115 H6 Altogether 
Sex* 
Male  (%)  40.7 60.7 51.9 51.9 47.4 49.5 48.9 
Female  (%)  59.3 39.3 48.1 48.1 52.6 50.5 51.1 
Age  * /mean  ± SD/  (yr)  70.7  ±10.4  68.3 ±  11.7  68.2 ±  10.8  67.8 ±11.0 63.1  ±13.2  69.7  ±11.9  67.3 ±  12.0  
Age 
groups* 
< 6 5  yr (%) 24.3 34.8 29.7 35.9 52.1 26.7 36.6 
65-75  yr (%) 37.6 36.0 42.9 36.4 27.0 37.1 35.0 
> 7 5  yr (%) 38.1 39.2 27.4 27.7 20.9 36.2 28.4 
Family 
background *  
Single  (%)  10.5 15.9 26.3 20.7 11.2 7.3 16.4 
In family (%) 89.5 84.1 73.7 79.3 88.8 92.7 83.6 
*  p<0.05  (in H1-H6  institutions)  
The  average  age  of  patients  was  also  different  in  the  different  institutions.  H5  had  the  
'youngest'  patients  with the  average  age  of  63.1  and  the  'oldest'  ones  came from HI  (70.7)  and  
H6 (69.7). 
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The  distribution  is  also  heterogeneous  concerning  different  age  groups:  in  H5  47.9  %  of  
patients  was  over  65  while  in  H6  and  HI  73.3  %  and  75.7  %  of  patients  belonged  to  this  age  
group,  respectively.  
Regarding family  background,  institutions  H3 and H6 should be mentioned,  as 26.3 % of the 
patients in the former hospital  and 7.3 % in the latter one lived on their  own.  
Socio-demographic  factors show a significant variation in case of the different institutions. 
4.5.2.  Hospitalization  indices  
As illustrated  by Table  4 the  admission  status  of  patients  to the  different institutions  reveals  
significant differences; 76.0 % of patients were brought to H3 as an emergency  and less than  one  
third  of the patients  in HI  and  H5 were  hospitalized  with urgency.  The regional  variation  in  the  
system of referring patients to hospital  highly contributes to the parameters  of admission  status.  
Table  4  Distribution  of the  most  important  hospitalization  indices (%)  in the different  institutions  
Character« 
Admission 
state  *  
Institutions 
tics  —__  
Urgent  (%)  
HI 
25.0 
H2 
64.7 
H3 
76.0 
H4 
58.5 
115 
29.5 
H6 
1.6 
Altogether 
48.6 
Non-urgent  (%)  75.0 35.3 24.0 41.5 70.5 98.4 51.4 
Nursing 
need  *  
Bedridden 19.3 22.7 5.2 52.0 12.0 47.3 24.5 
Self-catering 80.7 77.3 94.8 48.0 88.0 52.7 75.5 
Average  nursing  time  *  
/mean±SD/  (day)  
6.1±3.2 13.3±9.8 10.4±4.6 11.5±4.6 7.8±5.2 14.6±12.8 9.6±7.1 
* p<0.05  (in H1-H6  institutions)  
Some characteristic  data can represent the difference between  nursing  needs  in the  hospitals:  
nearly  half  of the patients  in institutions  H4  and  H6 was bedridden  (52.0  % and  47.3  %),  which  
means  that  the  percentage  of  severe  cases  in  these  two  hospitals  considerably  exceeded  the  
nursing-need  characteristics  of  all  the  patients  involved  in the  study.  In  institutions  H3  and  H5  
only  5.2  %  and  12.0  % of patients  was  bedridden  and,  at  the  same time,  94.8  % and  88.0  %  of  
them was ambulant.  
These  prominent  data  from Table  4  may  not  be  explained  by  inequalities  in  morbidity.  The  
question  is  whether  these  striking  differences  can  be  attributed  to  physicians'  attitude  and  
professional  background  or  to  the  deficiencies  in  information  and  methodology  in  the  period  
preceding  the  dissemination  of  the  guideline,  or  whether  the  strong  presence  of  traditions,  the  
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age-related  characteristics of physicians  and the influence of the "alma mater" attended  also play 
their  role.  Since  the  validity  of  the  data  was  not  controlled,  the  indices  of  nursing  needs  and  
admittance  status  (except  for  age  and  gender)  can  only  be  considered  informative.  It  is  very  
likely  that  both  outstanding  figures  regarding  bedridden  status  (5.2  %  and  52.0  %)  should  be  
regarded as extremes. 
The analysis of average  nursing  days  reveals that institutions HI  and H5 treated their  patients  
shorter  than the  average  (6.1  and  7.8 days),  while  institutions  H2 and  H6 were  characterized  by  
longer hospitalization  (13.3 and  14.6 days). 
4.5.3.  Initial  diagnoses  
As  illustrated  by  Table  5,  more  than  70  %  of  patients  in  institutions  HI,  H2  and  H6 were  
admitted to hospital  with the initial diagnosis of heart failure  [150]. 88.4 % of patients in H3 were 
diagnosed  initially  as  suffering from chronic  ischemic  heart  disease  [125], while  in H5 the  most  
frequent  initial  diagnoses  were  hypertensive  cardiac  disease  [111]  (29.5  %)  and  dilatative  
cardiomyopathy  [142] (24.5 %). 
Table  5  Distribution  of the  initial  diagnoses  (%)  in the different  institutions  
———  Institutions  
ICD-10 
HI 112 H3 H4 H5 H6 Altogether 
110  (Hypertonia)  *  4.9 5.6 0.9 6.9 1.9 7.6 4.0 
111  (Hypertensive  cardiac  disease)  *  - 3.4 0.5 - 29.5 - 9.0 
125 (Chronic  ischemic  heart disease)  *  3.1 4.5 88.4 14.7 17.3 4.8 23.8 
142 (Dilatative  cardiomyopathy)  *  1.3 2.2 7.1 8.7 24.5 1.9 10.6 
150 (Heart  failure)  *  73.0 77.5 0.5 55.4 13.6 74.3 40.1 
Other  initial diagnoses  *  17.7 6.8 2.6 14.3 13.2 11.4 12.5 
*  p<0.05  (in  H1-H6  institutions)  
The institutions  show  a significant difference concerning  the  other  diagnoses  as  well:  in  H6 
an average patient had 3 other diagnoses, while  in H4 the same figure was  8.5.  
There  were  significant  differences  between  the  institutions  regarding  both  the  initial  
diagnosis  and  the  average  number  of  other  diagnoses,  which  might  be  explained  by  
methodological  problems.  
4.5.4.  Classification  of status  on  admission  
Figure  12  showing  the  institutional  differences  in  NYHA  classes  on  admission  reveals  that  
almost half (46.1 %) of the patients in HI  was evaluated  as NYHA Class III.  
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NYHA Class IV dominated  in institutions  H2 and H3  (50.0 % and 69.2 %). 
Institutions  H4  and  H6  also  admitted  a  high  number  of  severe  cases  (H4 NYHA  Class  III:  
31.2 %, NYHA Class IV: 41.1  %, H6 NYHA  Class  III: 51.5 %, NYHA  Class  IV: 33.3 %).  More  
than  4/5  of  the  patients  in  the  latter  institution  were  admitted  with  severe  heart  failure  (NYHA  
Class  III-IV).  
Institution H5 admitted most of the mild cases (NYHA Class I:  17.0 %, NYHA Class II: 25.6 %). 
100% 
90% 
80% 
70% 
60% 
50% 
40% 
30% 
20% 
10% 
0% 
Figure  12  The  institutional  distribution  of NYHA  classes  on  admission  (%)  
4.5.5.  Medicinal  therapy  
Tables  6-9 comprise  information on the  application  of the  different active  agent  groups,  the  
use of which in the treatment  of chronic heart failure was recommended  by the  guideline.  
The  application  of  diuretics  (Table  6)  reveals  no  significant  differences  between  the  two  
examination  periods,  nor  can  we  detect  any  change  in the  practice  of  the  individual  institutions  
either.  With  a  few  exceptions,  the  hospitals  applied  the  same  active  agents  after  the  
dissemination of the guideline as before. The rate of application did not change  either.  
However,  there  are  some  institution-specific  uses  of  certain  pharmaceutical  preparations.  In  
H2,  furosemide, chlorthalidone  and  clopamide  were used  as diuretic  agents  in both  examination  
periods.  (Practically,  this  was  the  only  hospital  that  applied  a  significant  quantity  of  
chlorthalidone.)  In H5;  all types of diuretics were used in both examination  periods,  and this  was 
the only institution that used thiazide-based  diuretics.  
The most widely used diuretic  agents were furosemide and HCT+K-retaining  preparations  in  
all  institutions.  
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Table  6  Institutional  frequency of diuretics  (%)  in  both  examination  periods  
Institutions HI H2 H3 H 4 H 5 H6 
Inves t iga t ion 
^ ^ ^ p e r i o d s 
A c t i v e X . 
ingredients  ^ ^  
B A B A B A B A B A B A 
Th iaz ides 0 .6 0 . 5 - -
C l o p a m i d e  "  5.3 3 .7 8 .9 6 .8 - - 0.6 5.2 1.2 1.5 14.7 -
Chlor tha l idone  *  - - 2 4 . 4 2 2 . 7 - - 0.7 - 1.9 2 . 5 - 5.4 
Furosemide  *  71.1 76.1 7 7 . 8 8 6 . 4 68.9 90.3 88.1 83.5 4 5 . 7 4 4 . 2 72.1 86.5 
Ethacrynic  ac id  *  - 0.5 - - 14.3 8.6 16.4 17.5 1.9 3 . 0 7.4 5.4 
S p i r o n o l a c t o n e  *  7 .9 9.6 - 4.5 7.6 7.5 11.2 11.3 2 . 5 2 . 5 19.1 21.6 
K - c a n c r e o n a t e  *  2 .6 1.6 - - - - 6.0 1.0 2 . 5 4 .6 19.1 13.5 
HCT+K-sparing  *  44.7 32.4 6 .7 - 38.7 50.5 36.6 46.4 10 .5 16 .2 27 .9 16.2 
*  p<0.05  (in  H1-H6  institutions  in both  periods o f  time)  
#  p<0.05  (in  H1-H6  institutions  in the  'before'  period)  
When  considering  the differences in the  application  of ACE  inhibitors  (Table  7) between  the  
institutions, we can see that H2 applied  all ACE inhibitor preparations mentioned  in the table.  On 
the  other  hand,  institutions  H5  and  H6  used  only  three  preparations  (captopril,  enalapril,  
perindopril) while treating their patients. 
Table  7  Institutional  frequency  of ACE  inhibitors  (%)  in  both  examination  periods  
Institutions HI H2 113 H4 H5 H6 
Investigation 
A c ü ^ ^ e r i o d s 
ingredients  ^ ^ ^ ^  
B A B A B A B A B A B A 
Captopril  *  5.3 5.9 4.4 6.8 18.5 7.5 38.1 29.9 - 2.5 27.9 10.8 
Enalapril  *  42.1 52.1 57.8 56.8 24.4 43.0 33.6 28.9 56.2 56.3 24.9 37 .8 
Lisinopril  *  - - 6.7 2 .3 - 3.2 1.5 3.1 1.2 1.0 - 18.9 
Perindopril  *  5.3 10.1 13.3 15.9 3.4 4.3 3.0 8.2 8.6 7.6 1.5 5.4 
Benazepril" - • 2.2 2.3 - 1.1 3.7 - - 0.5 - -
Cilazapril 5.3 3.7 — 2.3 1.7 2.2 1.5 1.0 - 2.5 - -
Trandolapril - 1.1 2.2 4.5 - - - - - 0.5 - -
* p<0.05  (in H1-H6  institutions  in both  periods of  time)  
#  p<0.05  (in H1-H6  institutions  in the  'before'  period)  
Enalapril-  and  perindopril-based  ACE  inhibitors  were  widely  used  in  both  examination  
periods by all hospitals.  In H2, these two active agents constituted  about  3/4 of all ACE  inhibitor  
therapies.  Except  for  H5,  captopril  was  also  frequently  used  in  the  treatment  of  chronic  heart  
failure by  all  institutions.  The  rare  use  of  benazepril  and  trandolapril  was  only  characteristic  of  
some  institutions.  
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We can conclude  that  after the dissemination  of the  guideline  the pharmaceutical  practice  of  
the  individual  institutions  did  not  change  significantly,  i.  e. they  applied  the  same  active  agents  
with more or less the same frequency in both examination periods  [95].  
The  pharmaceutical  practice  of  the  individual  institutions  differed  in  the  order  of  applying  
diuretics and ACE inhibitors as well. 
Except  for  H3  (where  diuretic  monotherapy  was  preferred  -  44.8  %),  the  simultaneous  
application  of  diuretics  and  ACE  inhibitors  dominated  all  hospitals.  Institutions  HI,  H4  and  H6  
also had significant diuretic monotherapies  (27.4 %, 27.3 % and 29.5 %, respectively).  
In  case  of  H5,  besides  the  simultaneous  application  of  these  two  agents,  ACE  inhibitor  
monotherapies  also played  a significant role (27.0 %).  
Out  of  cardiac  glycosides,  digoxin  was  used  in  both  examination  periods  by  all  hospitals.  
Digitoxin  was  almost  exclusively  applied  in  H2,  where  its  application  frequency  changed  
significantly (from 13.3 % to 34.1 %) after the dissemination of the  guideline.  
Regarding  the  application  of  anticoagulants  (Table  8)  there  was  a  significant  difference  
between  the  individual  institutions.  The  most  types  of  anticoagulants  were  used  in  H4  in  both  
examination  periods;  the  other  hospitals  used  3-4  different  types  of  anticoagulants.  
Acenocoumarol  and acetylsalicylic  acid were used  in all  institutions.  
Table  8  Institutional  frequency  of anticoagulants  (%)  in  both  examination  periods  
Institutions HI H2 113 H4 H5 H6 
Investigation 
Active  periods  
ingredients 
B A B A B A B A B A B A 
Acenocumarol  *  13.2 19.1 55.6 34.1 23.5 19.4 45.5 39 .2 16.7 28.4 32.4 21.6 
Heparin  *  2.6 2.7 - - 7.6 6.5 32.8 10.3 5.6 8.6 4.4 -
Antithrombin  HI  - - - - - - 0.7 - - - - -
Nadroparin  *  - - 2.2 2.3 0.8 1.1 31 .3 34 .0 0.6 - - -
Na-pentosan-polysulfate 6.7 4.1 - - - 2.7 
Ticlopidin 3.7 3.1 1.2 1.0 - 2.7 
Acetylsalicylic  acid  *  13.2 13.3 11.1 18.2 30.3 29.0 28.4 33 .0 45.7 42.6 22.1 5.4 
Streptokinase - - - - - 1.1 - 1.0 - - - -
* p<0.05  (in H1-H6  institutions  in both periods  of  time)  
The  institutional  application  of  fi  blockers  and  nitrates  (see  Table  9)  can  be  summarized  as  
the following: 
The  most  frequently  used  13  blocker  was  metoprolol;  however,  there  are  significant  
differences in its application between the individual  hospitals.  
The  most  frequently  used  nitrates  were  nitroglycerin  and  isosorbide-mononitrate  in  both  
examination  periods;  nevertheless,  their  application  shows  significant  differences  between  the  
institutions participating  in this project. 
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Table  9  Institutional  frequency  of  B blockers  and  nitrates  (%)  in  both  examination  periods  
Institutions HI H2 113 H4 115 H6 
Investigation 
Ac tive  ~- ^ p e  rio ds 
ingredients 
B A B A B A B A B A B A 
fi  blockers  
Propranolol - - • 2.3 - 1.1 0.7 1.0 1.2 1.0 - 2.7 
Sotalol - - - - 0.8 1.1 0.7 - 0.6 1.0 • -
Metoprolol  *  15.8 23.4 13.3 11.4 17.6 10.8 33.6 30.9 31.5 40.1 19.1 24.3 
Atenolol - 0.5 - - 2.5 1.1 - 1.0 1.2 0.5 1.5 5.4 
Betaxolol - 1.1 - - - 1.1 - 1.0 - 0.5 - -
Bisoprolol - 4.8 - 2.3 0.8 3.2 4.5 4.1 4.9 4.1 - -
Nitrates 
Nitroglycerin  *  76.3 64.9 6.7 15.9 51.3 46.2 60.4 51.5 64.2 49.2 47.1 56.8 
ISDN - 0.5 - - - - 0.7 - - - - -
ISMN  *  18.4 20.2 15.6 29.5 17.6 20.4 50.7 56.7 11.7 21.3 7.4 10.8 
Other  nitrates  - 1.6 2.2 2.3 - - 0.7 6.2 0.6 4.1 - -
* p<0.05  (in H1-H6  institutions  in both  periods of  time)  
Table  10 shows the pharmaceutical  practice of the  individual  hospitals  according to the  main  
ATC  groups.  
Table  10  Institutional  frequency  of the  most  important ACE  inhibitor  preparations  (%)  
tuti o ns 
Drug  g r o u p s ^ ^ ^ ^ - ^ ^  
HI H2 H3 H4 H5 H6 
Diuret ics  *  93.8 97.8 91.0 92.2 57.1 94.3 
ACE inhibi tors  *  71.2 86.5 51.4 69.3 71.3 64.8 
Cardiac  g lycos ides  *  43.8 74.2 38.2 71.4 29.8 56.2 
Anticoagulants  *  32 .7 59.6 44.3 83.5 61.6 41.9 
Nitrates  *  86.7 32.6 65.1 87.0 70.8 57.1 
B blockers  *  27.4 16.9 19.8 38.1 43.7 25.7 
* p<0.05  (in H1-H6  institutions)  
Except for H5, all other hospitals used  diuretics  at a frequency of over 90 %. The use of  ACE  
inhibitors  was also frequent but the rate of application  differs significantly. H3 used the  smallest  
(51.4 %) and H2 used the highest amount of ACE inhibitors (86.5 %). 
The  most  cardiac  glycosides  were  used  in  H2  (74.2  %)  and  the  fewest  were  applied  in  H5  
(29.8 %). 
The two extremes regarding the use of anticoagulants  are HI  (32.7 %) and H4 (83.5 %). 
The  most  frequent  use  of  nitrates  occurred  in  institutions  HI  (86.7  %)  and  H4  (87.0  %),  
while H2 used the least of these preparations (32.6 %).  
H5 used the most fi blockers  (43.7 %) and the least was applied  in H2 (16.9 %). 
The  application  of  the  most  important  ACE  inhibitor  preparations  showed  a  significant  
divergence  between  the  six  hospitals  participating  in  the  project.  The  data  of  Table  11  support  
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that there was no significant difference in the pharmaceutical  practice  of the individual  hospitals  
between the two examination  periods.  
Table  11  The  institutional  application  of the  most  important  pharmaceutical  preparations  
in the two examination  periods  (%)  
Investigation  periods  Before After 
^ ^ ^ I n s t i  tuti ons 
Drug 
HI H2 H3 H4 H5 H6 HI H2 H3 H4 H5 H6 
Diuretics  *  97.4 95.6 85.7 92.5 57.4 91.2 93.1 100.0 97.8 91.8 56.9 100.0 
ACE inhibitors  *  57.9 88.9 47.1 72.4 67.9 60.3 73.9 84.1 57.0 64.9 74.1 73.0 
Cardiac  glycosides  *  52.6 73.3 34.5 70.1 32.1 54.4 42.0 75.0 43.0 73.2 27.9 59.5 
Anticoagulants  *  28.9 66.7 43.7 85.8 58.6 48.5 33.5 52.3 45.2 80.4 64.0 29.7 
Nitrates  *  94.7 24.4 65.5 87.3 73.5 52.9 85.1 40.9 64.5 86.6 68.5 64.9 
B blockers  *  15.8 17.8 21.8 38.1 39.5 20.6 29.8 15.9 17.2 38.1 47.2 31.5 
* p<0.05  (in  H1-H6  institutions  in both  periods o f  time)  
Summarizing  the  results  of  comparing  the  institution-specific  factors,  we  can  say  that  the  
hospitals  participating  in the  study  showed  significant differences in terms  of  sociodemographic  
parameters, way and status of admission,  and medicinal  therapy.  
4.6.  Multivariate  analyses  
There  is  no  doubt  that  we  should  consider  the  basic  differences  between  the  institutions  
participating  in  this  project  before  evaluating  the  influence  of  the  guideline  on  the  medicinal  
therapy of heart failure. 
In the  following, we  evaluate  the  influence of the  guideline  on the  application  of the  mostly  
recommended  pharmaceutical  preparations  (diuretics,  ACE  inhibitors,  cardiac  glycosides,  
anticoagulants)  after adjusting for the  differing parameters  of the  individual  institutions  both  in  
the 'before'  and 'after'  examination  periods.  
The  multivariate  analysis  was  carried  out  with  the  help  of  logistic  regression,  which  is  a  
widely  used model  system  in  statistical  analyses.  The model  describes the connection  between  a  
categorical  dependent  variable  (the application  of the different pharmaceutical  preparations)  and  
one or more  (categorical  or continuous)  independent  variables  [96].  In the example  illustrated  in  
Table  12  the  categorical  independent  variables  are  sex,  the  examination  period  and  the  
institution, while the continuous independent variable is age. 
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Table  12  Parameters  influencing the  application  of the  most  important  pharmaceutical  preparations  recommended  in  the  
treatment  of  heart  failure  
Characteristics 
Drug  groups  
Diuretics ACE  inhibitors  Cardiac  glycosids  Anticoagulants 
Estimated 
regression 
coefficient 
Signifi-
cance 
Odds 
ratio 
Estimated 
regression 
coefficient 
Signifi-
cance 
Odds 
ratio 
Estimated 
regression 
coeff icient 
Signifi-
cance 
Odds 
ratio 
Estimated 
regression 
coefficient 
Signifi-
cance 
Odds 
ratio 
Sex  a  0.3766 0 .0334 1.4574 0.0016 0.9901 1.0016 0.4595 0 .0003 1.5833 0.5222 0 .0000 1.6857 
Age 0.0417 0 .0000 1.0426 -0.0016 0.7720 0.9984 0.0341 0 .0000 1.0347 -0.0016 0.7667 0.9984 
Invest period  a  -0.2567 0 .1506 0.7736 -0.2459 0.0621 0.7820 0.0022 0 .9868 1.0022 0.0825 0 .5276 1.0860 
Institution  o  - 0 .0000 - - 0.0000 - - 0 .0000 - - 0 .0000 -
HI 0.0700 0.8546 1.0725 -0.0094 0.9650 0.9907 -1.2620 0.0000 0.2831 -2.2978 0.0000 0.1005 
112 1.2565 0.0981 3 .5132 1.0304 0.0026 2.8021 0.0856 0.7656 1.0894 -1.2943 0.0000 0.2741 
H3 -0.1768 0.6105 0.8379 -0.7629 0.0001 0 .4664 -1.4543 0.0000 0.2336 -1.8782 0.0000 0.1529 
HS -2.0677 0.0000 0.1265 0,0528 0.7783 1.0543 -1.6583 0.0000 0.1905 -1.1405 0.0000 0.3197 
H6 0.3345 0.4974 1.3972 -0.1852 0.4586 0.8310 -0.7407 0.0031 0.4768 -1.9712 0.0000 0.1393 
Constant -0.3116 0.5658 - 1.0647 0.0114 - -1.6075 0.0002 - 1.4376 0.0007 -
o  Reference  categories:  female  
after  period  
H4 
According to the results of the multivariate  analysis, the examination  period  (i.  e. the  periods  
before  and  after  the  dissemination  of  the  evidence-based  guideline)  did  not  influence  
significantly  the  application  of  the  pharmaceutical  preparations  in  any  of  the  groups.  However,  
the  effect of  the  institution  was  statistically  evident  in  all  groups.  In  the  case  of  diuretics  and  
cardiac  glycosides  sex and age are the most influential factors, while  anticoagulant  application  is  
influenced  by  sex  mainly.  We  can  also  conclude  that  in  H2  the  chances  of  receiving  a  diuretic  
treatment  are  3.5 times,  while the chances  of receiving  an ACE inhibitor treatment  are 2.8  times  
higher  than  they  would  be  in  H4,  which  was  the  reference  institution.  At  the  same  time,  in  H3  
only  every  second  patient  has  the  chance  to  receive  an  ACE  inhibitor  treatment,  which  would  
comply with the recommendations  of modern pharmaceutical  practice.  These  data emphasize  the  
existence and the determining role of regional differences in health care.  
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5.  Discussion  
The  concept  of  evidence-based  medicine  is  not  a  new  one.  It  means  that  in  the  course  of  
patient  care  health  service  providers  make  their  decisions  meticulously  with  regard  to  the  
individual patient on the basis of the best available (literary, statistical, empirical) information. 
The expertise and personal wisdom that medical practitioners may acquire during their work 
constitute  the  "personal  component"  in  EBM.  This  personal  component  can  manifest  itself  in  
efficient and effective diagnostic skills, in reasoned statements, in the personal empathy with the 
suffering of patients  and their  human  dignity,  and  in decisions  made in the best  interest  of  the  
patient. By "external  component" of EBM we mean the best  available external theories that are 
exclusively based on relevant research results, which mainly come from patient-centered  clinical  
research [97].  
Congestive heart failure is a circulatory disorder, sometimes it is called "the silent epidemic"; 
this disease is the leading cause of death in developed industrialized countries. 22 million people 
are at risk worldwide and half of the patients will die within a 5-year period after establishing the 
diagnosis. The mortality rate is six times higher than it was 40 years ago [40]. The mortality and 
morbidity  indicators  are  on  the  increase  as  well,  the  population  is  aging,  the  average  life  
expectancy  gets higher;  the prevalence  of  heart  failure is the  highest  in  case  of  people  65  and  
over. Heart failure represents a major problem in health care all over the world since the chronic 
disease is  accompanied  by high mortality  rate,  and  it  carries reduced  life quality, the  incidence  
has increased, and the demand for treatment and hospital care of patients is immensely high. The 
large  amount  of  required  drugs,  the  devices  that  are  implanted  (pacemaker,  defibrillator,  
resyncronizator),  and in certain cases the only solution, the heart transplantation  costs a lot,  and 
they  impose  a  great  burden  on  health  care.  The  care  of  patients  suffering  from  heart  failure  
presents  a  considerable  task  for  cardiologists,  internal  specialists  and  general  practitioners  
working in primary health care as well. 
A  large  spectrum  of  cardiovascular  research  deals  with  heart  failure  with  regard  to  its  
significance.  As  a  result  of  these  investigations  a  new  approach  has  appeared  in  specialized  
literature  called  the  "neurohormonal  model"  of  heart  failure.  This  model  indicates  that  the  
concept  of  circulatory  failure syndrome  of  cardiac  origin  includes  all  neurohormonal  reactions  
that have an effect on the functioning of the whole body  i.e. "heart  failure is not  only  a failing 
heart".  On  the  basis  of  this  new  approach  the  standard  treatment  of  heart  failure  has  been  
complemented,  so today besides diuretics  and digitalis, primarily ACE inhibitors are prescribed 
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that have an effect on the renin-angiotensin system (RAS) and research deals primarily with new 
therapies that influence the neurohormonal regulating systems [35,40].  
It is expedient to carry out modern medicinal therapy of chronic heart failure on the basis of 
the  results  presented  by  comprehensive  multi-centered  clinical  tests,  and  after establishing  the  
correct diagnosis, the pathophysiological  background, the initial disease, the precipitating factors 
and the state of clinical severity. 
In  the  treatment  of  cardiovascular  diseases  nitroglycerin  and  acetylsalicylic  acid  have  a  
leading  role  and they  are  a  hundred  years  old,  while  digitalis  is two  hundred  years  of  age  but  
their  exact  effect mechanism  is not  yet  fully understood.  It  is  surprising  that  the  first  research 
findings in connection with the renin-angiotensin  system were published in  1898 by scientists of 
the Karolinska Institute in Stockholm. The inhibition of the angiotensin-converting  enzyme as a 
potential  new  group  of  drugs  for hypotensive  treatment  was  first described  in  1977.  Blocking  
RAS  with  ACE  inhibitors  is  able  to  slow  down  the  progression  of  several  cardiovascular  
diseases,  and  improves  life  expectancy  as  well  [98,99].  Over  the  past  decade  ACE  inhibitors  
have become the favorites in the often "fashion-conscious" world  of applied therapies.  The use 
of  ACE  inhibitors  in  case  of  different  syndromes  of  cardiovascular  diseases,  such  as  
hypertension, heart muscle infarct, congestive heart failure, is not only recommended but also in 
most  cases  obligatory.  This  "fashion-consciousness" is  not  without  foundation  since  EBM  has  
provided numerous convincing data in connection with the indispensable use of ACE inhibitors;  
the only exception is the intolerance of these drugs [100]. 
Standard  therapies  should  be  performed  with  efficient  dosages  of  medicine.  It  is  
characteristic of the Hungarian regional health care provision that the patients concerned are not 
always  treated  with  the  efficient, appropriate  dosages  of  medicine.  Further  shortcomings  are  
present in providing information and in patient education  [40,101,102].  
The  present  study  demonstrates  the  practice  of  medicinal  therapy  in  case  of  patients  with  
chronic  heart  failure  in  Hungary.  We  have  compared  the  medicine  provision  of  hospitalized  
patients  in two  examined  periods.  Our  comparison  was  of  a  rather  epidemiological  nature;  the  
cardiologist  aspect,  in the  strictest  sense  of the  word  was  less prevalent.  Our  objective was  to  
make a survey about the Hungarian practice of health care, to what extent it is able to keep pace 
with evidence-based medicine, and to examine what effect the dissemination of guideline had on 
the  daily  care  of patients  suffering from heart  failure. On the  basis  of  our  findings we  can  say  
that  in  the  six  Hungarian  health  care  institutions  volunteering  to  participate  in  the  project  the  
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medicine  provision  of  patients  suffering  from  heart  failure  met  the  requirements  of  modem  
medicinal  therapy  in  the  period  before  the  dissemination  of  the  evidence-based  practice  
guideline.  In  the  period  after  the  dissemination  of  the  practice  guideline  developed  by  the  
AHCPR a significant change could be observed in the volume of drug use in case of 2 of the 4 
main  classes  of  drugs  recommended  for  standard  treatment  of  heart  failure -  diuretics,  ACE  
inhibitors,  cardiac  glycosides  and  anticoagulants  -  in  comparison  with  the  period  before  the  
dissemination  of  the  guideline.  ACE  inhibitors  were  more  frequently  used  and  anticoagulants  
were more rarely  applied by the hospitals in the 'after'  examination period than  in the  'before'  
period. With regard to the use of other two classes of drugs -  diuretics and cardiac glycosides  -
there was no statistically relevant change comparing the two periods. 
One  of  the  main  objectives  of  the  application  of  practice  guidelines  is  the  balancing  of  
diversities in clinical practice besides supporting decision-making.  Since we were well aware of 
the  considerable  differences that  exist  in  the  different  fields  of  Hungarian  health  care,  it  was  
essential  to  be  fully informed  about  the  characteristics  of  medicinal  therapy  of  the  individual  
institutes  participating  in  the  project  in  both  periods.  On  the  basis  of  the  findings  of  this  
examination  we  can  say  that  the  dissemination  of  the  guideline  did  not  have  a  considerable  
impact  on  the  practice  of  medicinal  therapy  in  the  hospitals,  since  the  differences  that  
fundamentally exist between the inpatient institutions,  and which can be experienced  also in the 
therapeutic  approach  of  heart  failure,  could  not  be  balanced  by  the  time  of  the  'after'  period  
either.  Regional  health  care  differences (in  our  case  differences in  drug  dispensation)  can  be  
observed in clinical practice. The leveling of these differences cannot be proved on the basis of 
our findings although it could have been expected from the application of the guideline. 
This fact is highly unsatisfactory in itself. In order to form the final, research-based  opinion  
about  the  impact  of  the  practice  guideline,  it  is  inevitable  that  the  different parameters  of  the  
institutions  are taken  into  consideration  as  well.  The  multivariable  analyses  in  the third major 
part of our experiment have shown that the examination period i.e. the fact that the guideline had 
been disseminated  did not have any influence on the application  of any group of drugs used in 
heart failure but in each case the institutions had a significant impact on the application of drugs. 
On the basis of the results of the logistic regression analysis it can be stated that the changes in 
drug  application that  were  expected  to be  effects of the practice  guideline  were not  due to  the  
dissemination of the guideline but these changes were the result  of the fundamental differences 
in  medicinal  therapy  applied  in  the  different  institutions  participating  in  the  project.  The  
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medicinal treatment of the inpatients with chronic heart failure is largely institution-specific and 
this was not  influenced by the  dissemination  of die  guideline.  Similar  results were provided by 
the  analyses  of  echocardiography  examinations,  which  are  applied  very  successfully  in  the  
diagnosis of left-ventricular systolic dysfunction [51]. 
As  far  as  the  implementation  methodology  of  the  evidence-based  practice  guideline  is  
concerned,  the  following  conclusions  can  be  made,  which  may  affect  the  outcome  of  the  
examination.  The  Hungarian  Ministry  of  Welfare  -  as  an  academic  coordinator  -  and  the  
Consultation Center for Quality Improvement  in Health Care under the umbrella of the Ministry 
of Welfare -  as a practical  coordinator  - took  an active part  in the  Hungarian  adaptation  of  the 
guideline developed by AHCPR. Due to their co-operation and mutual assistance their tasks such 
as  translating  the  guideline  into  Hungarian,  modifying the  guidelines  in  order  to  make  them  
adaptable in Hungary after a consensus seeking period, informing the project coordinators of the 
institutions  participating  in the project, carrying  out  a pilot  study prior to the  examination  and  
performing the necessary modifications on the basis of the findings of the pilot study, completing 
the instructions  so that the data sheets are filled in a uniform manner,  sending the data sheets to 
the  institutions,  determining  the  time  span  of  the  examination  periods  and  collecting  the  data  
sheets  filled  in  by  the  hospitals  on  the  basis  of  their  patient  documentation  were  all  well  
coordinated and performed quite successfully. There was no central regulation by the Ministry as 
to the dissemination  of the guideline within the hospitals  and to the translation  of the  guideline  
into everyday practice. The hospitals performed these tasks individually within their own sphere 
of  authority  with  the  help  of  the  project  coordinators,  and  taking  the  local  conditions  and  
facilities  into  consideration  as  well.  It  seems  that  the  individual,  institution-specific  
implementation  of  the  practice  guideline  could  not  achieve  the  expected  results.  Culture,  
customs, traditions and various interests in health care practice turned out to be stronger than the 
latest research results.  The Health Act of  1997 made it  compulsory to  apply practice  guidelines  
but there is no such forum that determines what practice guidelines mean. In addition, the control 
of  professional  work  in  hospitals  is  not  carried  out  entirely  either.  The  introduction  of  
professional  accreditation  is  a  current  issue  lately,  and  it  can  considerably  contribute  to  the  
regard for scientific evidences in the course of providing health care. 
As  for  the  documentation  of  drug  application  during  inpatient  hospital  stay,  the  
denomination,  the  daily  dosage  and  the  period  of  indication  of  the  drug  used  in  heart  failure  
therapy  were  registered  correctly  but  the  form of  application,  the potency  of the  drug  and  the  
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packaging units were  indicated  rather  incompletely.  Therefore, due to the  lack  of reliable  data,  
provision costs could not be examined although it had been one of the objectives of the project. 
Precise and high-level  documentation actually influences the quality of medical treatment  in  
the  given patient  care  unit/department  favorably since it affects the physicians/staff performing 
the  documentation,  and the  quality  of patient  care  as well.  At the various  levels  of health  care,  
control  is  largely  based  on the  examination  of  documentation.  Continuous  control  of  medical  
documentation is an integrated part in die system of quality assurance in health care. Even if the 
most sophisticated method is applied, the efficiency of this control can only be guaranteed if the 
control  is permanently  sustained  and frequently performed. Unfortunately the publication of the 
continuous  control  in medical  documentation,  and the  concrete results  of this control  are rather  
poor in Hungary [103].  
On the basis  of  the results  outlined  in this  study, we  can  claim that  only  the translation  of  
professionally  well-founded  and  internationally  accepted  practical  guidelines  into  therapeutic  
practice can be justified. If we consider our examination as a model for approaching the impact  
study of evidence-based practical  guideline from an epidemiological point of view, on the basis 
of our findings we can suggest  a more extended  regulation  of conditions in the  implementation  
of the guidelines, and quality improvement of data provision and documentation. If these aspects 
are taken into consideration, there is a hopeful possibility and a performable expectation that the 
implementation  and  application  of  practical  guidelines  will  reduce  regional  differences  and  
increase the standard quality of health care in Hungary. 
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6.  Summary  
Over the last decade great importance has been attached to the attempts for achieving quality 
patient  care.  The  increase  in  regional  differences  can  be  detected  in  the  changes  in  health  
condition  and  in  patient  care  practice  as  well.  A  possible  device  for  improving  quality  is  the  
application of practical  guidelines.  
The  objective  of  our  research,  the  examination  of the  adaptability  and  impact  study  of  the  
evidence-based  practical  guideline  developed  by the  AHCPR,  "Heart Failure: Evaluation and 
Care of Patients with Left-Ventricular Systolic Dysfunction" was to  study the Hungarian  health  
care of patients with chronic heart failure, and to examine the effect of the recommendations  of  
the above mentioned guideline on the inpatient hospital care. 
We  used  the  'before-after'  epidemiological  method  in  our  study.  The  present  thesis  
demonstrates the examination of one of the treatment options, the medicinal treatment of patients 
with chronic heart failure. 
Our  findings  show  that  in  compliance  with  the  recommendations  of  the  evidence-based  
practical  guideline the application  of ACE inhibitors has  significantly increased,  and the use of 
anticoagulants  decreased.  There  was  no  statistically  relevant  change  in  the  application  of  
diuretics and cardiac glycosides in the period after the dissemination of the guideline. 
In the six health institutions the drugs recommended for the treatment of chronic heart failure 
were used quite extensively -  but at the same time quite dissimilarly  in the various  institutions.  
The  diversity  balancing  effect  of  the  practical  guideline  could  not  be  detected  either  in  the  
variety of the applied drugs or in their amount. 
According to the findings of the multivariable  examination, the examination period did not, 
but the institution did affect significantly the medicinal therapy in case of all groups of drugs. 
Our  results  put  great  emphasis  on  the  existence  and  strong  predominance  of  regional  
differences in health care. Providing quality health care can only be achieved realistically if these 
differences  are  leveled,  and  careful  and  elaborated  implementation  and  application  of  the  
practical guidelines and continuous monitoring of the hospitals are realized. 
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